Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
04/2010 | Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions April category listing, related patent applications 04/10

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
04/29/2010 > patent applications in patent subcategories. category listing, related patent applications

20100105602 - Treatment of intracellular bacterial infections: The present invention relates to methods for treating intracellular bacterial infections with defensin polypeptides.... Agent: Novozymes North America, Inc.

20100105601 - Method for treating a synucleinopathy: The present invention relates to methods for restoring fast axonal transport in a cell which expresses a pathological synuclein protein and for treating a synucleinopathy using a Protein Kinase C mu or Src-Family Tyrosine Kinase inhibitor.... Agent: Licata & Tyrrell P.C.

20100105603 - Methods and preparations for curing clinically ill patients: This invention relates to a life saving medicament for critically ill patients and a method of treatment. The composition is a pharmaceutically effective amount of a blood glucose regulator which is used to control the blood glucose level.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100105604 - Allyloxy and alkyloxy benzoic acid delivery agents: The present invention relates to pharmaceutical compounds for delivering active agents, such as biologically or chemically active agents, to a target. The invention also relates to pharmaceutical compositions comprising at least one delivery agent compound of the present invention and at least one active agent, and unit dosage forms comprising... Agent: Emisphere Technologies, Inc. C/o Darby & Darby P.C.

20100105605 - Fatty acid formulations and oral delivery of proteins and peptides, and uses thereof: Fatty acid compositions for administration of of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition formulated for oral administration by ingestion, having from about 0.1 to about 75% w/w fatty acid component, where the... Agent: Moore & Van Allen PLLC

20100105606 - Methods for making high oxygen affinity modified hemoglobin for oxygen transport: The present invention relates to blood products, and more particularly to compositions comprising a modified oxygenated hemoglobin having a high affinity for oxygen and methods for making such compositions. Such compositions according to the present invention have better stability to autooxidation and superior oxygen carrying characteristics.... Agent: The Nath Law Group

20100105607 - Novel semi-synthetic glycopeptides as antibacterial agents: Semi-synthetic glycopeptides having antibacterial activity are described, in particular, the semi-synthetic glycopeptides described herein are made by chemical modification of the a glycopeptide (Compound A, Compound B, Compound H or Compound C) or the monosaccharide made by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in... Agent: Wilson, Sonsini, Goodrich & Rosati

20100105608 - Peptides and methods using same for diagnosis and treatment of amyloid-associated disease: Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X-Y or Y-X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100105609 - Processes for preparing eptifibatide: The present invention provides, inter alia, convergent processes for preparing eptifibatide that involve coupling a 2-6 eptifibatide fragment to an activated cysteinamide residue to form a 2-7 eptifibatide fragment, attaching a mercaptopropionic acid residue to the 2-7 eptifibatide fragment through disulfide bond formation, coupling the peptide intramolecularly, and removing the... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz And Cohn

20100105612 - Agent containing fused protein of soluble rankl with epitope tag: The present invention provides a reagent containing a fused protein of RANKL with an epitope tag that has improved effects of differentiating and activating osteoclasts and improved preservation stability compared with the case of using RANKL alone, and an agent for differentiating and activating osteoclasts that can be used in... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100105617 - C-terminal attachment of two chemical groups to peptides: The present invention relates to a method for C-terminal attachment of two property-modifying groups to a peptide.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100105624 - Calcitonin drug-oligomer conjugates, and uses thereof: Calcitonin drug-oligomer conjugates that include a calcitonin drug coupled to an oligomer including a single polyalkylene glycol moiety consisting of between 4 and 10 polyalkylene glycol subunits are disclosed. Pharmaceutical compositions including such conjugates and methods of treating bone disorders by administering such conjugates are also disclosed.... Agent: Moore & Van Allen PLLC

20100105619 - Cysteine-containing peptides having antioxidant properties: Cysteine containing amphipathic alpha helices of the exchangeable apolipoproteins, as exemplified by apolipoprotein (apo) A-IMilano (R173C) and apoA-IParis, (R151C) were found to exhibit potent antioxidant activity on phospholipid surfaces. The addition of a free thiol, at the hydrophobic/hydrophilic interface of an amphipathic alpha helix of synthetic peptides that mimic HDL-related... Agent: Townsend And Townsend And Crew, LLP

20100105611 - Method of treating respiratory disorders: The invention relates to the use of agents that bind the complement protein C5 in the treatment of diseases associated with inappropriate complement activation, and in particular in the treatment of respiratory disorders.... Agent: Klauber & Jackson

20100105610 - Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells: The invention provides compositions comprising one or more isolated factors from a microenvironment of human embryonic stem cells (hESCs), including, but not limited to, Lefty and inhibitors of Nodal. The invention also provides methods of utilizing factors derived from human embryonic stem cells (hESC) and their microenvironment to treat and... Agent: K&l Gates LLP

20100105618 - Non-natural recombinant gelatins with enhanced functionality: The invention concerns recombinant gelatin monomers and recombinant gelatins comprising or consisting of multimers of the monomers. The recombinant gelatins can be produced with enhanced stability.... Agent: Morgan Lewis & Bockius LLP

20100105615 - Nutritional composition to promote healthy development and growth: A nutritional composition for improving the immunological function of a subject, including a lipid or fat; a protein source; about 5 to about 100 mg/100 kcal of a source of long chain polyunsaturated fatty acids which comprises docosahexanoic acid; and about 0.1 to about 1 mg/100 kcal of a prebiotic... Agent: Waddey & Patterson, P.C.

20100105616 - Polyethylene glycol-g-csf conjugate: The present invention relates to three-branched PEG-G-CSF conjugate of general formula (1) in which the bonding ratio of three-branched polyethylene glycol (PEG) and G-CSF is 1:1 (mol/mol), wherein PEG has an average molecular weight of from 200 to 45,000 daltons; a pharmaceutical composition comprising the same, and a preparing method... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100105620 - Polypeptides that bind trail-r1 and trail-r2: Agonists for TRAIL death receptors including polypeptides having a multimerizing, e.g. trimerizing, domain and a polypeptide sequence that binds to at least one of TRAIL death receptors TRAIL-R1 and TRAIL-R2. Agonists are described that do not bind to TRAIL decoy receptors. The multimerizing domain may be derived from human tetranectin.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100105622 - Protein product for treatment of infectious diseases and related inflammatory processes: The inventors have found that CD6, a member of the Scavenger Receptor Cysteine-Rich (SRSR) superfamily expressed on human lymphocytes binds to Gram-positive and Gram-negative bacteria, as well as to other microbial structures. Thus, a CD6 product is useful for the manufacture of a medicament for therapeutic and/or preventive treatment of... Agent: Roberts Mlotkowski Safran & Cole, P.C. Intellectual Property Department

20100105623 - Schizophrenia-related isoform of kcnh2 and development of antipsychotic drugs: The invention is related to a novel primate specific brain isoform of the potassium channel KCNH2 and genetic association with risk for schizophrenia.... Agent: Nih-ott

20100105613 - Therapeutic agent for occlusive peripheral vascular disease, and use thereof: A study was made on the therapeutic effect of midkine on an occlusive peripheral vascular disease, and it was found that midkine has an activity of promoting neovascularization and that a blood vessel can be proliferated and the blood flow in the upper and lower limbs can be improved (in... Agent: Morrison & Foerster LLP

20100105621 - Therapies for acute renal failure: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of, acute renal failure, or subject to, or at risk of, inflammation, neutrophil-mediated cell damage, and apoptosis resulting from tissue damage or injury. The methods involve the administration... Agent: Ropes & Gray LLP

20100105614 - Ultra low dose doxepin and methods of using the same to treat sleep disorders: The invention relates to doxepin, pharmaceutically acceptable salts and prodrugs of doxepin; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep disorders.... Agent: Knobbe Martens Olson & Bear LLP

20100105625 - Product and methods for diagnosis and therapy for cardiac and skeletal muscle disorders: Disclosed are products and methods to promote myoblast activation and cardiac and skeletal muscle growth or regeneration, and to treat heart and skeletal muscle diseases, based on the identification of cellular processes affected by prelamin A processing.... Agent: Sheridan Ross PC

20100105626 - Novel analogues of antimicrobial and anticancer peptide synthesized and produced from gaegurin 5: The present invention is related to antimicrobial and anticancer peptide engineering using Gaegurin 5 isolated from Korean frog (Rana rugosa), which have smaller structure compared with previously known Gaegurin peptide and shows potent antimicrobial and anticancer activity. Specifically, the antimicrobial and anticancer peptide of the present invention synthesized from the... Agent: Kirk Hahn

20100105627 - Pharmaceutical compositions and related methods of delivery: The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The... Agent: Lando & Anastasi, LLP

20100105629 - N-substituted peptidomimetic inhibitors of dipeptidylpeptidase iv: One aspect of the present invention relates to inhibitors of post-pro line protease enzymes, such as inhibitors of dipeptidyl peptidase IV (DPIV). Other aspects of the invention relate to pharmaceutical compositions and methods of use thereof. In certain embodiments, a DPIV inhibitor comprises a carboxylic acid-containing side chain moiety at... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100105628 - Reducing post-operative adhesion formation with intraperitoneal glutamine: Glutamine source formulations that have release profiles that provide for sustained release via intraperitoneal administration of glutamine reduces post-operative adhesion formation.... Agent: Knobbe Martens Olson & Bear LLP

20100105630 - Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders: Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and/or prevention of neurodegenerative disorders and autoimmune disorders.... Agent: Merchant & Gould PC

20100105631 - Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence: wherein X is a radical of scyllo-inositol wherein one or more of R1, R2, R3, R4, R5, and R6 are independently alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioalkyl,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100105759 - H19 silencing nucleic acid agents for treating rheumatoid arthritis: The invention relates to the treatment of rheumatoid arthritis, particularly to the use of nucleic acid agents capable of silencing H19 for the treatment of rheumatoid arthritis. The invention provides methods for ameliorating rheumatoid arthritis and symptoms associated therewith, utilizing gene silencing oligonucleotides such as small interfering RNA (siRNA) agents... Agent: Winston & Strawn LLP Patent Department

20100105760 - Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1: Oligonucleotide compounds modulate expression and/or function of an apolipoprotein (ApoA1) polynucleotides and encoded products thereof. Methods for treating diseases associated with apolipoprotein-A1 (ApoA1) comprise administering one or more Oligonucleotide compounds designed to inhibit the Apo-A1 natural antisense transcript to patients.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100105758 - Use of an adenosine antagonist: Uses for a selective adenosine A3 receptor antagonist, or RNAi directed against said receptor, to treat myocardial infarction and heart conditions including heart failure, are provided. Optionally, an adenosine A2a receptor agonist may also be used with the adenosine A3 receptor antagonist. Methods of treating heart failure are also provided.... Agent: Quine Intellectual Property Law Group, P.C.

20100105762 - Therapeutic agent for periodontal disease and alveolar bone loss due to surgery: By suppressing transcription activation by NFκB, the present invention was demonstrated to suppress alveolar bone resorption in periodontal disease models, and promote restoration of alveolar bone in periodontal disease-caused bone defect models. Therefore, the present invention provides agents for treating, preventing, and improving periodontal diseases and alveolar bone defects caused... Agent: Foley And Lardner LLP Suite 500

20100105761 - Treatment of pain through expression of opioid receptors: Disclosed are compositions and methods related to nucleic acid constructs containing a HUMOR encoding element. These constructs can be used in the treatment of pain.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100105632 - Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals: The present invention relates to compositions for the protection, treatment and repair of connective tissues in humans and animals comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothionine,... Agent: Arent Fox LLP

20100105633 - Process: The invention relates to a process for the preparation of water-soluble chitosan salts, to chitosan products produced by this process and to their uses, e.g. in pharmaceutical or veterinary compositions or as a food or cosmetic additive. More specifically, the invention relates to a process for preparing a water-soluble chitosan... Agent: Bacon & Thomas, PLLC

20100105634 - Use of glucosamine as a mental and physical stress recovery enhancer and a performance enhancer: The present invention provides a composition comprising glucosamine salts or derivatives for rapid enhancement of at least one of mental performance and physical performance of a subject. The composition enhances the mental performance and physical performance by reducing at least one kind of cellular stress effects in the body of... Agent: Cargill, Incorporated

20100105635 - Composition for prevention or treatment of disease associated with amyloidosis through inhibition of amyloid protein aggregation and promotion of amyloid protein degradation: e

20100105636 - T-type calcium channel blocker:

20100105637 - Drug-surfactant complexes for sustained release: The invention involves sustained-release pharmaceutical compositions containing a water-soluble ionic small molecule pharmaceutical agent complexed with an oppositely charged surfactant, particularly a natural bile surfactant. The complexes are sustained-release ionic complexes. The complexes release the ionic pharmaceutical agents into aqueous solution slowly and with zero-order kinetics. Thus, they can be... Agent: Hugh Mctavish Mctavish Patent Firm

20100105638 - Cosmetic compositions: The present invention relates to the use of ascorbyl phosphate and niacinamide to suppress the crystallization of biotin in cosmetic or dermatological compositions. Furthermore, the invention relates to cosmetic or dermatological compositions comprising ascorbyl phosphate, niacinamide, biotin and a cosmetically acceptable carrier.... Agent: Nixon & Vanderhye, PC

20100105639 - Mesalamine suppository: The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Yet another embodiment... Agent: Darby & Darby P.C.

20100105640 - Aromatase inhibitors for emergency contraception: There is disclosed an emergency contraceptive preparation which comprises at least one aromatase inhibitor wherein the preparation comprises at least one dose for administration on one or more days to a female patient following an unprotected sexual encounter until the establishment or continuation of pregnancy of the patient is prevented.... Agent: Dann, Dorfman, Herrell & Skillman

20100105641 - Oral contraceptive spray: The subject invention provides a liquid contraceptive formulation for oral transmucosal administration. The formulation comprises etonogestrel, optionally together with ethinyl estradiol but does not contain a matrix former or a percutaneous absorption promoter, which is a hydroxy acid or a salt thereof.... Agent: Organon Usa, Inc. C/o Merck

20100105644 - Botanical composition for enhanced skin repair and uses thereof: A skin augmentation composition comprises a therapeutically effective amount of a combination of a gingerol and a curcumin and a cosmetically or pharmaceutically acceptable carrier. Methods for enhancing the repair of damaged skin and the prevention of developing wounds in a subject having damaged skin comprises administering to a portion... Agent: Harness, Dickey & Pierce, P.L.C

20100105642 - Novel compounds 409: s

20100105643 - Ophthalmic composition: It has now been found that tetrahydrocortisol alone, when in solution or in the form of nanoparticles, or a combination of compounds where each affects intraocular pressure by a different mechanism of action is especially valuable for the treatment of elevated intraocular pressure and glaucoma, especially in the resistant patient.... Agent: Gabriel Lopez

20100105646 - Allopregnanolone in a method for enhancing neurological function (alzheimer disease): Neuro-enhancing agents, compositions and methods are disclosed herein. Preferred neuro-enhancing agents of the present invention include progesterone and metabolites of progesterone, such as 3α-hydroxy-5α-pregnan-20-one (THP). These agents yield neuro-enhancing effects on neural cells that include neural progenitor and/or stem cells, whereby the agents stimulate mitosis of neural progenitor cells, stimulate... Agent: Pabst Patent Group LLP

20100105645 - Inhibition of ppar gamma expression by specific osteogenic oxysterols: This invention relates to methods for using agents to inhibit peroxisome proliferator activated receptor expression.... Agent: Venable LLP

20100105647 - Amide compound and use thereof for controlling plant diseases: Disclosed is an amide compound represented by the following formula (1). (1) (In the formula, X1 represents a fluorine atom or a methoxy group; X2 represents a hydrogen atom, a halogen atom, a C1-C4 alkyl group or the like; Z represents an oxygen atom or a sulfur atom; and A... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100105648 - Solid pharmaceutical composition comprising (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chroman: The invention relates to a solid pharmaceutical preparation containing (R)-(−)-2-[5-(4-fluorophenyl-3-pyridylmethylaminomethyl]chroman as an active substance and at least one sugar alcohol (e.g. mannitol, sorbitol) as a filler. Also disclosed is the production of said solid pharmaceutical preparation, which is provided with an increased shelf life also at elevated temperatures and can... Agent: Millen, White, Zelano & Branigan, P.C.

20100105649 - Veterinary compositions for treating mastitis: The present invention relates to a veterinary composition for the prophylaxis and treatment of mastitis in mammals, preferably cows. The formulations of the present invention comprise two parts that are optionally administered to the animal as a blended formulation or two separate formulations. The first part is a seal formulation... Agent: Pharmacia & Upjohn

20100105651 - Antagonists of sns sodium channels: Compounds of the formula (I), and pharmaceutically acceptable salts thereof, are found to be antagonists of SNS sodium channels. They are therefore useful as analgesic and neuroprotective agents, formula (I): R1 represents: (a) -L-A or -L′-A′ wherein L represents a bond or a C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl... Agent: Banner & Witcoff, Ltd.

20100105650 - Substituted isoquinoline and isoquinolinone derivatives: m

20100105655 - Novel compounds 515:

20100105652 - Purines as cysteine protease inhibitors:

20100105653 - Pyrrolopyrimidine compounds and their uses: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity... Agent: Novartis Institutes For Biomedical Research, Inc.

20100105654 - Substituted quinazolinone compounds: A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structures VA, VB, VIIA and VIIB where the values of the variables are defined herein.... Agent: Foley & Lardner LLP

20100105656 - Triazolopyrazine derivatives: v

20100105657 - Compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity a: The present invention relates to new compounds of formula (I), or salts, solvates or solvated salts thereof, process for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in the treatment of 5-HT6 mediated disorders such... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100105658 - Aza-bridged-ring compound: [Means for Solving Problems] The present inventors have made studies on a compound having an antagonistic action on the binding of a muscarinic M3 receptor, and they have found that an aza-bridged-ring compound or a salt thereof has an antagonistic action on the binding of a muscarinic M3 receptor, thereby... Agent: Fitzpatrick Cella Harper & Scinto

20100105659 - 2-aminopyridine analogs as glucokinase activators: Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.... Agent: Viksnins Harris & Padys Pllp

20100105660 - 2-aminopyridine analogs as glucokinase activators: A compound of formula (I), or tautomers, or stereoisomers, or solvates, or pharmaceutically acceptable salts thereof, wherein M1, M2, L1, L2, W1, W2, X1, X2, Y1, Y2, A, R5 and R5a are as defined herein for the for treatment of conditions treatable by the blockade of an epithelial sodium channel,... Agent: Novartis Institutes For Biomedical Research, Inc.

20100105662 - Besifloxacin ophthalmic composition for the treatment or control of infection: A composition comprises besifloxacin in an amount effective for treating or controlling an infection caused by an antibiotic-resistant bacterium. Such a composition can be administered to a subject for the treatment or control of bacterial conjunctivitis caused bay an antibiotic-resistant bacterium.... Agent: Bausch & Lomb Incorporated

20100105661 - Condensed pyridine compound: More specifically, it has been verified that since the compound according to the present invention has inhibitory activity against JAK3, the compound is useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transduction (e.g., rejection during live organ/tissue transplantation, autoimmune diseases,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100105663 - 2-(heteroaryl) alkyl indazole 6-phenyl and thienyl methyl amide as thrombin inhibitors: The invention relates to substituted indazoles and methods for production thereof and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, especially of cardiovascular diseases, preferably of thromboembolic diseases.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100105664 - Organic compounds: e

20100105665 - Renin inhibitors:

20100105666 - Triazabenzo (a)naphtho(2,1,8-cde) azulene compounds.:

20100105668 - Quinazoline derivatives:

20100105667 - Quinoxaline- and quinoline-carboxamide derivatives:

20100105669 - Plant health composition: The present invention relates to a composition containing (A) at least one specific carbamate fungicide, (B) at least one specific insecticide and optionally (C) at least one azole, the use of this composition for improving plant health and a method for improving plant health by treating a plant, its propagules... Agent: Birch Stewart Kolasch & Birch

20100105670 - Fungicidal mixtures: Also disclosed is a fungicidal composition comprising a fungicidally effective amount of the aforesaid mixture and at least one additional component selected from the group consisting of surfactants, solid diluents or liquid diluents. Further disclosed is a method for controlling plant diseases caused by fungal plant pathogens comprising applying to... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100105671 - C7-fluoro substituted tetracycline compounds: s

20100105672 - Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of... Agent: Jones Day

20100105673 - Substituted aminofuranones and their use: The present invention relates to novel substituted aminofurans, to methods for their preparation, to their use in the treatment and/or prophylaxis of diseases as well as their use in the manufacture of medical products for the treatment and/or prophylaxis of diseases, in particular retroviral disorders, in humans and/or animals.... Agent: Edwards Angell Palmer & Dodge LLP

20100105674 - Chemical compounds: The present invention relates to dianilinopyrimidine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such dianilinopyrimidine derivatives are useful in the treatment of diseases associated with inappropriate Wee1 kinase activity.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100105676 - Fused heterocyclic compounds useful as kinase modulators: Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, [PLEASE INSERT CHEMICAL STRUCTURE HERE] (I) are useful as kinase modulators, including Btk modulation, wherein R1, R2, R4, Q, Y, A and D are as defined herein.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100105677 - Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (e.g., indazoles and benzothiazoles), which... Agent: Millen, White, Zelano & Branigan, PC

20100105675 - 11 beta-hsd1 modulators: e

20100105679 - 5-pyridinone substituted indazoles: Various 5-substituted 1-substituted indazoles are described, as are pharmaceutical compositions containing these compounds and methods of treatment of diseases using these compounds. Other embodiments are also described.... Agent: Nixon Peabody LLP - Patent Group

20100105678 - Novel anxiolytic compounds: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.... Agent: Wolf Greenfield & Sacks, P.C.

20100105681 - 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors: The present invention concerns 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.... Agent: Hoxie & Associates LLC

20100105680 - Substituted dimethylcyclobutyl compounds, their preparation and use in medicaments: The present invention relates to substituted dimethylcyclobutyl compounds of general formula I, a process for their preparation, medicaments comprising said substituted dimethylcyclobutyl compounds as well as the use of said substituted dimethylcyclobutyl compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or... Agent: Knobbe Martens Olson & Bear LLP

20100105683 - Compounds useful for inhibiting chk1: Aryl- and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome... Agent: Eli Lilly & Company

20100105682 - Cyclopropyl-piperazine compounds as calcium channel blockers: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type calcium channel activity are disclosed. Specifically, a series of compounds containing both a piperazine ring and a cyclopropyl ring are disclosed of the general formula (I) where X1 and X2 are linkers.... Agent: Morrison & Foerster LLP

20100105684 - Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments: The present invention relates to heterocyclyl-substituted-tetrahydro-naphthalen-amine compounds of general formula (I) and compositions thereof, methods for their preparation, and the use of said compounds for the treatment or prophylaxis of various disorders of humans or animals.... Agent: Heslin Rothenberg Farley & Mesiti PC

20100105685 - S-nitrosothiol compounds and related derivatives: The present invention is directed to a method of treating a lack of normal breathing control including the treatment of apnea and hypoventilation associated with sleep, obesity, certain medicines and other medical conditions. In an aspect, the invention is directed to treating disordered control of breathing by administering an composition... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100105686 - Phenylsulfamoyl benzamide derivatives as bradykinin antagonists: R1-R8 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective antagonists of bradykinin B1, to processes for producing these same compounds, pharmacological compositions containing them and to their use in therapy or prevention of painful and... Agent: Fish & Richardson P.C.

20100105687 - Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds: Disclosed herein are methods of treating a patient suffering from a cognitive disorder using compounds of the following formula, Formula (2), wherein the variables have the meaning defined in the specification.... Agent: Allergan, Inc.

20100105688 - Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1: The present invention relates to pharmaceutical compositions comprising an NK1 receptor antagonist and a sodium channel blocker, wherein at least one of them is at subtherapeutic dose, as a combined preparation for simultaneous or sequential administration, and to the use of such compositions in the treatment of certain disorders, including... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100105689 - Novel 1,4- and 1,5-diarylsubstituted 1,2,3-triazoles useful as potassium channel modulators: This invention relates to novel 1,4- and 1,5-diarylsubstituted 1,2,3-triazole derivatives that are found to be potent modulators of potassium channels and, as such, they are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to modulation of potassium channels.... Agent: Birch Stewart Kolasch & Birch

20100105690 - Lisofylline analogs and methods for use: Analogs of a Lisofylline (LSF), and synthetic methods for the preparation of such analogs are provided. The analogs of LSF provided have the ability to protect cell viability, particularly the ability to protect pancreatic β-cells.... Agent: Prout And Associates, LLC

20100105692 - Dipterinyl calcium pentahydrate (dcp) and therapeutic methods based thereon: Provided herein is dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon. Also provided herein is the compound dipterinyl calcium pentahydrate (DCP) or an analog or polymorph thereof.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100105691 - Metformin folate and preparation of the same: The present invention discloses a novel biguanidine compound, i.e. folacin-metformin, and its manufacture with inorganic salt of metformin as raw material. Compared with metformin, the compound has the same clinic curative effect, such as lowering blood sugar, curing poly-cystic ovary syndrome (PCOS), losing weight and so on, without resulting in... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100105693 - Modulators of muscarinic receptors: The present invention relates to substituted piperazine compounds that are useful modulators of muscarinic receptors. The present invention also provides compositions comprising such compounds, and methods for treating muscarinic receptor mediated diseases.... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz & Cohn LLP

20100105694 - Substituted pyrazinone derivatives for use as a medicine: The present invention concerns substituted pyrazinone derivatives according to the general Formula (I) a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in claim 1, having selective 2C-adrenoceptor antagonist activity.... Agent: Philip S. Johnson Johnson & Johnson

20100105695 - Method for enhancing insulin secretion: The invention is directed to methods for enhancing endogenous insulin levels in a patient in need thereof which method comprises administering to the patient an insulin secretion-enhancing amount of racemic ranolazine or the R- or S-enantiomer of ranolazine. It is also directed to methods of treatment comprising racemic ranolazine or... Agent: Cv Therapeutics, Inc. Gilead Palo Alto, Inc.

20100105696 - Imidazoquinolines as dual lipid kinase and mtor inhibitors: in the treatment of mammalian target of rapamycin (mTOR) kinase dependent diseases, methods of use of said compounds in the treatment of said diseases in a warm-blooded animal, especially a human, pharmaceutical preparations comprising said compounds for the treatment of said diseases and said compounds for use in the treatment... Agent: Novartis Corporate Intellectual Property

20100105697 - Therapeutic agents: The present invention is directed to therapeutic agents of the formula (I) which are atypical antipsychotics and which are useful in the treatment of neurological and psychiatric disorders associated with dopamine D2 and serotonin 5-HT2A neurotransmission dysfunction. wherein; R1 is C1-6alkyl, which is unsubstituted or substituted with 1-6 fluoro, wherein... Agent: Merck

20100105698 - Therapeutic methods and compounds: The invention provides diketopiperazines of formula I. The invention also provides pharmaceutical compositions comprising the diketopiperazines, or pharmaceutically-acceptable salts or prodrugs thereof, as the active ingredient. The invention further provides therapeutic treatments that utilize the diketopiperazines of formula I, including inhibition of a proliferative disease or condition, inhibition of angiogenesis,... Agent: Sheridan Ross PC

20100105699 - Crystalline base of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine: Crystalline base of compound trans-1-(1R,3S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine, processes for the preparation of purified free base or salts of this compound, pharmaceutical compositions comprising the base and medical use thereof, including for treatment of schizophrenia and other psychotic disorders.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20100105700 - Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors: Provided herein are inhibitors of CYP17 enzyme. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100105702 - heterocyclylethylamide derivatives: A compound of general formula (I). A process for preparing this compound. A fungicide composition comprising a compound of general formula (I). A method for treating plants by applying a compound of general formula (I) or a composition comprising it.... Agent: Ostrolenk Faber Gerb & Soffen

20100105701 - Gyrase inhibitors and uses thereof: The present invention relates to compounds which inhibit bacterial gyrase and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals. The present invention also relates to a method... Agent: Vertex Pharmaceuticals Inc.

20100105703 - Synthetic mimetics of host defense and uses thereof: The present invention provides arylamide compounds and methods of making and using them as antibiotics.... Agent: Pepper Hamilton LLP

20100105704 - 7-(3',4'-dialkoxyphenyl)-[1,2,4]-triazolo[1,5-a]pyrimidine compounds, process for preparing thereof, and pharmaceutical composition for treating or preventing asthma, chronic obstructive pulmonary disease, arthritis, atopic dermatitis, tumor and degenerat: The present invention relates to novel {7-(3′,4′-dialkoxyphenyl)-[1,2,4]-triazolo[1,5-a]pyrimidine compounds or pharmaceutically acceptable salts thereof, a process for preparing the same, and pharmaceutical compositions for treating or preventing inflammatory diseases including asthma and chronic obstructive pulmonary disease, arthritis, atopic dermatitis, cancers including leukemia, and degenerative brain diseases including Alzheimer's disease, depression and... Agent: The Webb Law Firm, P.C.

20100105706 - Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists: The present invention relates to methods of preventing airway remodeling using A2B adenosine receptor antagonists. This invention finds utility in the treatment and prevention of asthma, COPD, pulmonary fibrosis, emphysema, and other pulmonary diseases. The invention also relates to pharmaceutical compositions for use in the method.... Agent: Cv Therapeutics, Inc. Gilead Palo Alto, Inc.

20100105705 - Purinyl derivatives and their use as potassium channel modulators: This invention relates to novel purinyl derivatives and their use as potassium channel modulating agents. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels.... Agent: Birch Stewart Kolasch & Birch

20100105707 - Method of treating or preventing oxidative stress-related disease: Disclosed is a method of treating or preventing an oxidative stress-related disease in a mammal in need thereof comprising administering an effective amount of a compound of formula (I) to the mammal, wherein R1-R4 and X1-X3 are as described herein. Examples of the oxidative stress-related diseases are a neurological disorder,... Agent: Leydig, Voit & Mayer, Ltd.

20100105708 - Pyrrolopyrimidines for pharmaceutical compositions: The present invention relates to novel pyrrolopyrimidine compounds of the general formula (1) and pharmaceutical compositions comprising said pyrrolopyrimidine compounds. Moreover, the present invention relates to the use of the pyrrolopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can... Agent: Lando & Anastasi, LLP

20100105709 - Heteromonocyclic compound and use thereof: R3 and R4 are each H, or C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, di(C1-C6)alkylamino or C1-C6 alkylthio, each of which is optionally substituted; and R5 is H, or C1-C6 alkyl, C2-C6 alkenyl, cyclic group, each of which is optionally substituted, —CO—R8 or —O—R8′, or a salt thereof. The... Agent: Foley And Lardner LLP Suite 500

20100105710 - Solid preparation comprising 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-4-fluorobenzonitrile: The present invention provides a solid preparation containing 21[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluorobenzonitrile (compound (A)) or a salt thereof as a pharmaceutically active ingredient. Specifically, the present invention provides a solid preparation containing a granule composed of compound (A) or a salt thereof and an additive (excluding microcrystalline cellulose) and a tablet containing (a)... Agent: Foley And Lardner LLP Suite 500

20100105712 - Chemical compounds: Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100105711 - Organic compounds: r

20100105714 - Furanone compounds and methods of making and using the same: The invention features compounds of the general Formula (I): (formula should be inserted here) Compounds of Formula (I) possess unexpectedly high affinity for Alk5 and/or Alk4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders.... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz And Cohn

20100105713 - Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders: wherein R6, R7, R9, R10, R11, X, n, p, Ar and m are as defined in the description. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100105715 - Polymer conjugates of opioid antagonists: The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the... Agent: Jones Day

20100105716 - Camkk(beta) as a target for treating obesity: A method of treating a condition in a subject in need thereof, comprising administering a calcium/calmodulin dependency kinase kinase (CaMKK) inhibitor in a treatment-effective amount. Conditions which may be treated include obesity (particularly adult obesity), insulin resistance (including high fat diet-induced insulin resistance), hyperglycemia (including hyperglycemia accompanying obesity), diabetes, etc.... Agent: Myers Bigel Sibley & Sajovec

20100105717 - Tacrolimus for improved treatment of transplant patients: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It... Agent: Darby & Darby P.C.

20100105718 - Naphthalene and quinoline sulfonylurea derivatives as ep4 receptor antagonists: The invention is directed to naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.... Agent: Merck

20100105719 - Imidazolidine carboxamide derivatives as lipase and phospholipase inhibitors: e

20100105721 - Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications: The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to imidazo[1,2-a]pyridine containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or... Agent: Connolly Bove Lodge & Hutz LLP

20100105720 - Preparation and utility of substituted imidazopyridine compounds with hypnotic effects: The present disclosure is directed to modulators of GABAA receptors and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment and/or management of sleep disorders and/or for providing a patient in need with a hypnotic, anxiolytic or anti-convulsive effect... Agent: Global Patent Group - Apx

20100105722 - Substituted 4,5,6,7-tetrahydrothienopyridines as kcnq2/3 modulators: e

20100105723 - 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazo[4,5-b]pyridin-2-one derivatives useful as a2b adenosine receptor antagonists:

20100105724 - Crystalline and amorphous forms of palonosetron hydrochloride: Amorphous and polymorphic of palonosetron hydrochloride are disclosed that can be characterized by X-ray powder diffraction patterns, thermal properties, purity and methods of manufacture. These forms of palonosetron hydrochloride can be produced from solution or by solid state interconversions. The forms can be used in pharmaceutical formulations: particularly preferred uses... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100105725 - Antidiabetic bicyclic compounds: Diaryl ethers in which one of the aryl groups is a phenyl fused to a cycloalkyl or heterocyclic ring, to which is attached an acetic acid group, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus,... Agent: Merck

20100105726 - Imidazole derivatives that induce apoptosis and their therapeutic uses: The present invention relates to a pharmaceutical composition comprising compound for induction of apoptosis, a method for inducing cancer cell apoptosis, a method to suppress lymphocyte activation, a method to improve intracellular trafficking of misfolded mutants and a screening method to identify additional compounds useful for inducing apoptosis, and more... Agent: Cantor Colburn, LLP

20100105727 - Novel benzamide derivatives and process for the prepartion thereof: The present invention provides a novel benzamide derivative represented by formula 1 and an isomer, a pharmaceutically acceptable salt or hydrate thereof, and a composition for activating a 5-HT<sb>4</sb> receptor comprising the same, as an active ingredient. Benzamide derivatives of the present invention has superior affinity for 5-HT<sb>4</sb> receptors, capability... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100105728 - Dihydro-[1h]-quinolin-2-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes: e

20100105729 - Aryl-substituted heterocyclic pde4 inhibitors as anti-inflammatory agents: Disclosed herein are potent and selective aryl-substituted heterocyclic compounds, useful as inhibitors of phosphodiesterase 4 (PDE4), compositions comprising the same, and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of PDE4 activity are also provided, as well as methods for the treatment of inflammatory diseases and... Agent: Global Patent Group - Kal

20100105730 - Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine: Liquid formulations of the DL-lactic acid, the glutaric acid, the L-aspartic acid and the glutamic acid salts of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine and their use in the manufacture of a medicament to be used in the treatment of CNS diseases are provided.... Agent: Darby & Darby P.C.

20100105732 - Piperidine gpcr agonists: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.... Agent: Osi Pharmaceuticals, Inc.

20100105731 - Novel benzamidine compound: m

20100105733 - Treatment of vasomotor symptoms with selective estrogen receptor modulators: The present invention is directed toward methods for treating vasomotor symptoms, (e.g., hot flashes and night sweats) in a patient in need thereof comprising administering a SERM as described herein.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100105734 - Treatment xerophthalmia with norketotifen: Methods of using a cycloheptathiophene compound for the treatment of xerophthalmia are described, as are formulations and compositions for such treatment.... Agent: Nields, Lemack & Frame, LLC

20100105735 - Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain: Compositions, methods and systems for administration of small volume sufentanil-containing drug dosage forms to the oral mucosa of a subject are disclosed.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP/acelrx

20100105736 - N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles: m

20100105737 - Pyridine derivatives substituted with heterocyclic ring and gamma-glutamylamino group, and antifungal agents containing same:

20100105738 - Extended release formulations of a proton pump inhibitor: The invention provides extended release formulations of proton pump inhibitor, such as an extended release formulation of rabeprazole, comprising an amount of rabeprazole between 30 and 90 mg rabeprazole and having an AUC of between 900 and 1750 ng*hr/mL and other properties.... Agent: Nixon & Vanderhye, PC

20100105739 - Modulators of atp-binding cassette transporters: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz & Cohn LLP

20100105740 - O-substituted-dibenzyl urea-derivatives as trpv1 receptor antagonists: The invention relates to compounds of formula (I) in which R is selected from halogen, alkyl, alkoxy, aryl and heteroaryl; R1 is selected from 2-hydroxyethyl, 2,3-dihydroxypropyl, 3-hydroxypropyl, 2,2-dihydroxyethyl, 3,3-dihydroxypropyl, 1,3-dioxolane-ethyl, 1,3-dioxane-methyl, 1,3-dioxolane-methyl, 1,3-dioxane-ethyl, 3-fluoro-2-hydroxypropyl, 3-car-boxy-2-hydroxy-propyl, 3-chloro-2-hydroxypropyl, 2-hydroxypropyl, 2-hydroxy-propen-2-yl, morpholinoethyl, piperazinoethyl, hydroxymethyl, benzyl, 4-(hydroxymethyl)benzyl, 4-chlorobenzyl, 4-fluorobenzyl, and 4-hydroxybenzyl. R2 is te/t-butyl... Agent: Steinfl & Bruno

20100105741 - Administration of pyridinedicarboxylic acid compounds for stimulating or inducing the growth of human keratinous fibers and/or arresting their loss: in which R1 and R2 represent, independently of one another, OH, OR′, —NH2, —NHR′ or —NR′R″, and R′ and R″ represent, independently of one another, a saturated or unsaturated and linear or branched C1-C18 alkyl radical or an aryl radical, this alkyl or aryl radical optionally being substituted by at... Agent: Buchanan, Ingersoll & Rooney PC

20100105742 - Pearlescent liquid cosmetic composition: A pearlescent liquid cosmetic composition and process for preparation is provided herein. The composition includes 14-25% of a C12-C22 fatty acid; 0.1-1.8% of an alkali metal C12-C22 fatty acid soap by weight of the composition; 0.1-10% niacinamide; and 20-85% water. The lustre effect is achieved by careful control of the... Agent: Unilever Patent Group

20100105743 - Pharmaceutical compositions and methods for stabilizing the same: Pharmaceutical compositions, and a method of stabilizing pharmaceutical compositions having clevidipine, or any pharmaceutically acceptable salt thereof, as the active ingredient is described. The method includes the slowing down or inhibiting of the oxidation pathway of clevidipine. This can be accomplished by reducing the amount the pharmaceutical composition is exposed... Agent: Gibbons P.C.

20100105744 - Substituted 7-sulfanylmethyl-, 7-sulfinylmethyl- and 7-sulfonylmethylindoles and the use thereof: The present application relates to novel 7-sulfanylmethyl-, 7-sulfinylmethyl- and 7-sulfonylmethylindole derivatives, processes for the preparation thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases, and the use thereof for the manufacture of medicaments for the treatment and/or prevention of diseases, especially for the treatment... Agent: Barbara A. Shimei Director, Patents & Licensing

20100105745 - Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta: It is intended to provide a novel means of treating and diagnosing cancer by clarifying the participation of glycogen synthase kinase 3β (GSK3β) in the survival and proliferation of cancer mils. Namely, a method of suppressing the survival and proliferation of cancer cells by inhibiting the expression of GSK3β or... Agent: Birch Stewart Kolasch & Birch

20100105746 - Method for treating metabolic diseases: A method for treating a condition of low metabolic rate, dyslipidemia, excess adiposity and/or insulin resistance, or a disease or syndrome characterized by one or more of said conditions in a subject, comprises administering to the subject a therapeutically effective amount of romazarit or a pharmaceutically acceptable salt, ester or... Agent: Harness, Dickey, & Pierce, P.l.c

20100105747 - Hydroxymethyl ether hydroisoindoline tachykinin receptor antagonists: The present invention is directed to certain hydroxymethyl ether hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their... Agent: Merck

20100105748 - Methods and compositions for treatment of drug addiction: The present disclosure relates to methods of treating a stimulant addiction of a patient comprising administering to a patient in need a therapeutically effective dose of a selective dopamine β-hydroxylase inhibitor thereby decreasing stimulant reward, inducing aversion for the stimulant or preventing relapse in the patient. The disclosure further encompasses... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20100105749 - Chemical compounds, pharmaceutical compositions and methods: The present invention provides compounds of the formulae (I) and (II), and derivatives thereof, for the treatment of cardiovascular conditions... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100105750 - Stable metronidazole gel formulations: The invention provides aqueous gel compositions comprising metronidazole, benzyl alcohol as a solvent, water, and a polyacrylic acid or cellulosic gelling agent, wherein the benzyl alcohol is present in an amount effective to maintain the physical stability of the aqueous gel composition for at least seven days at 5° C.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100105751 - Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes: The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, hepatic disorders, and/or cardiometabolic disorders.... Agent: Vance Intellectual Property, PC

20100105752 - Crystalline modification of fipronil: The present invention relates to a crystalline modification of fipronil, to a process for the preparation of the same, to pesticidal and parasiticidal mixtures and compositions comprising said crystalline modification and to their use for combating pests and parasites.... Agent: Brinks, Hofer, Gilson & Lione

20100105753 - Inhibitors of fibroblast activation protein, and methods of use thereof: One aspect of the present invention relates to synthetic peptide derivatives that inhibit fibroblast activation protein α (FAP) activity. Another aspect of the invention relates to methods for treating a mammal suffering from cancer by administering a therapeutically effective amount of synthetic peptides derivatives that inhibit FAP activity.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100105754 - 5-(4phenyl)prolinamide for treatment of epilepsy: e

20100105755 - Substituted benzamide modulators of dopamine receptor: The present invention relates to new substituted benzamide modulators of dopamine receptor, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group, LLC

20100105756 - Method of treating down syndrome: The present invention relates to methods of treating of Down syndrome in a person using compounds of the invention.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100105757 - Treatment and inhibition of disease conditions using flexible heteroarotinoids: The present invention contemplates methods of treating, reducing, inhibiting or preventing several diseases by the administration of flexible heteroarotinoids. Among the diseases or conditions which can benefit from treatment with flexible heteroarotinoids as described herein are, (1) cancers and other diseases that involve abnormal differentiation, (2) diabetes, (3) hemophelia, (4)... Agent: Dunlap Codding, P.C.

20100105763 - Pharmaceutical composition, health food composition and inos inhibitors, containing theopederin derivatives: The present invention relates to a pharmaceutical composition and a health food composition for the prevention and treatment of immune- and autoimmune diseases such as septic shock, hemorrhagic shock, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease and multiple sclerosis, and metabolic diseases such as arteriosclerosis and type II diabetes, and an... Agent: Cantor Colburn, LLP

20100105765 - Combination therapy for effecting weight loss and treating obesity: e

20100105764 - Use: There is provided a method for the manufacture of a medicament for the treatment of cancer comprising a compound capable of inhibiting a steroid sulphatase enzyme (E.C.3.1.6.2), wherein the cancer is of a type, in which the cancer cells overexpress aromatase enzyme.... Agent: Frommer Lawrence & Haug

20100105766 - Composition for inhibition or prevention of bone density reduction: The present invention relates to a composition for the inhibition or prevention of a bone mineral density reduction, or food and drink for use in such application, comprising isoxanthohumol or an isomerized hop extract as an active ingredient. According to the present invention, a bone mineral density reduction can be... Agent: Foley And Lardner LLP Suite 500

20100105767 - Compounds, compositions and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100105768 - Mold-inhibiting method and composition: Disclosed is a method for inhibiting the growth of mold on building materials by application onto and/or incorporation into the building material of a mold-inhibiting composition comprising dehydroacetic acid or a salt thereof and, optionally, an additional fungicidal agent such as a quaternary ammonium compound. A preferred application of the... Agent: Hoffmann & Baron, LLP

20100105769 - pharmaceutical composition containing daurinol for the prevention and treatment of cancers: The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising daurinol as an active ingredient, more precisely a pharmaceutical composition for the prevention and treatment of cancer comprising daurinol isolated from the medicinal plant of Mongolia, Haplophyllum dauricum or Haplophyllum cappadocicum, as an active... Agent: Lucas & Mercanti, LLP

20100105770 - Therapeutic delivery of carbon monoxide: Compounds, pharmaceutical compositions and methods for the therapeutic delivery of carbon monoxide to humans and other mammals that employ Mn complexes having CO ligands, and additional halogen, monodentate and/or bidentate ligands, wherein the additional ligands do not occupy trans positions relative to each other.... Agent: Wolf Greenfield & Sacks, P.C.

20100105771 - Amino acid salts of prostaglandins: The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.... Agent: Michael Best & Friedrich LLP

20100105772 - Use of novel lipid mediators to inhibit angiogenesis: The present invention is generally drawn to novel isolated therapeutic agents, termed lipoxins, generated from the interaction between a dietary omega-6 polyunsaturated fatty acid (PUFA) such as arachidonic acid (AA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20100105773 - Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularization: The present invention relates to methods and compositions for the treatment of, or prevention of angiogenesis in a subject. In particular, the present invention relates to methods to treat a subject with, or at risk of developing angiogenesis by administering a pharmaceutical composition comprising a resolvin or resolvin analogue or... Agent: David S. Resnick

20100105774 - Antidepressant: An antidepressant containing, as an active ingredient, at least one compound selected from a branched amino acid, a pharmaceutically acceptable salt thereof and a derivative thereof.... Agent: Hogan & Hartson L.L.P.

20100105775 - Amino acid salts of prostaglandins: The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.... Agent: Michael Best & Friedrich LLP

20100105776 - Use of malachite green in the form of drug for treating malignant neoplasms: The use of malachite green in the form of a tetramethyldiamino-triphenyl-carbinol anhydro-oxalate [(C23H25N2)—(C2HO4)]2—C2H2O4 of the following structural formula as a drug for treating malignant neoplasms administered in a single doze of 1 to 2 g. Malachite green can be used when dissolved in an aqueous solution or in a physiological... Agent: Pauley Petersen & Erickson

20100105777 - Amide or thioamide derivatives and their use in the treatment of pain: The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of pain and disorders related thereto as well as a method for treatment of pain and disorders related thereto, wherein said compounds are administered. The compounds... Agent: Cara Therapeutics, Inc. Intellectual Property Department

20100105778 - Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain: The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100105779 - Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain: The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100105780 - Colchicine compositions and methods: Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.... Agent: Cantor Colburn, LLP

20100105781 - Abuse resistant lysine amphetamine compounds: The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such... Agent: Darby & Darby P.C.

20100105782 - 2,3,3-trimethylcyclopent-3-enecarbaldehyde derivatives useful as odorants: e

20100105783 - Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same: A method and packaging machine for preparing rapidly disintegrating formulations for oral administration are disclosed. The present invention is characterized in that a powdery mixture including a pharmaceutically active ingredient and a sugar or a sugar alcohol powder is filled into a packaging material and, thereafter, the mixture, filled in... Agent: Bacon & Thomas, PLLC

20100105784 - Pharmaceutical pellets comprising modified starch and therapeutic applications therefor: Vaginal use compositions comprising pellets prepared from a debranched starch. Pellets may be conveniently prepared via extrusion/spheronization.... Agent: Henkel Corporation

  
04/22/2010 > patent applications in patent subcategories. category listing, related patent applications

20100099600 - Candidates against infection: The present invention relates to the use of plasminogen/plasmin and its derivatives as agents for enhancing host defense against infection or other infectious diseases. The invention also relates to a method for screening of compounds which enhance host defense against infection by evaluating the host defense against bacterial arthritis and... Agent: Morrison & Foerster LLP

20100099601 - Fibrillation-resistant insulin and insulin analogues: A fibrillation-resistant insulin analogue may be a single-chain insulin analogue or a physiologically acceptable salt thereof, containing an insulin A chain sequence or an analogue thereof and an insulin B chain sequence or an analogue thereof connected by a polypeptide of 4-10 amino acids. The fibrillation-resistant insulin analogue preferably displays... Agent: Hahn Loeser & Parks, LLP

20100099603 - Lyophilized recombinant vwf formulations: The present invention provides long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations.... Agent: Marshall, Gerstein & Borun (baxter)

20100099602 - Pharmaceutical compositions and methods of use for the prevention and treatment of hypoxic injury: The invention is directed to compositions and methods for using the same for the prevention and treatment of hypoxic conditions, ischemia/reperfusion injury and the sequels thereof.... Agent: Hoffmann & Baron, LLP

20100099604 - Peptidic and non peptidic ligands for immunodetection of the receptor for urotensin: The use of opportunely modified specific ligands of the receptor for urotensin II (UTR) or antibodies (commercially available) raised against the same receptor as tools for the definition of both the differentiation and the prognosis of human prostate adenocarcinoma is described, moreover, the use of opportunely radiolabeled ligands for UTR... Agent: Abelmabn Frayne & Schwab

20100099605 - Chaperonin 10 immunosuppression: The invention is directed to the use of cpn10 in transplantation and particularly to treatment and/or prevention of graft versus host disease. The invention provides a method of administration of cpn10 to a donor and/or recipient animal or cells, tissues or organs derived from the donor, although in a particularly... Agent: Foley & Lardner LLP

20100099606 - Effective use method of medicaments and method of preventing expression of side effect: e

20100099611 - Anti-angiogenic peptides: A purified polypeptide includes about 10 to about 40 amino acids and has an amino acid sequence corresponding to a portion of SEQ ID NO: 2. The polypeptide can inhibit binding of VEGF to VEGFR2 of cells that express VEGFR2.... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20100099614 - Antimicrobial peptides and methods of use: Disclosed herein are antimicrobial peptides with useful and/or superior properties such as specificity, resistance to degradation, antimicrobial activity, desirably low levels of hemolytic activity, and a therapeutic index against a broad range of microorganisms including gram-negative, gram-positive and acid-fast bacteria, fungi and other organisms. Also provided are pharmaceutical compositions comprising... Agent: Greenlee Winner And Sullivan P C

20100099625 - Bio-security system: A method for preventing contamination of a teat during administration of a sealant comprises the steps of introducing/delivering a sterilising agent into the teat and subsequently delivering the sealant into the teat. A sealant injector 1, has a nozzle 3, with a removable protective cap 2. A sterilising agent 4... Agent: Jacobson Holman PLLC

20100099607 - Casein complexes: Complexes comprising resveratrol and a casein, a process for their manufacture, their uses and compositions comprising them.... Agent: Nixon & Vanderhye, PC

20100099623 - Cross-linked collagen and uses thereof: The present invention discloses collagen cross-linked in a micro to non-fibrillar form and at a high concentration. The cross-linked collagen gel has improved volume stability or persistence than collagen cross-linked at a neutral pH. Also disclosed are methods for preparing the inventive cross-linked collagen and using such for augmenting soft... Agent: Allergan, Inc.

20100099624 - Cross-linked collagen and uses thereof: The present invention discloses collagen cross-linked in a micro to non-fibrillar form and at a high concentration. The cross-linked collagen gel has improved volume stability or persistence than collagen cross-linked at a neutral pH. Also disclosed are methods for preparing the inventive cross-linked collagen and using such for augmenting soft... Agent: Allergan, Inc.

20100099621 - Disodium salts, monohydrates, and ethanol solvates for delivering active agents: R5 is a substituted or unsubstituted C2-C16 alkylene, substituted or unsubstituted C2-C16 alkenylene, substituted or unsubstituted C1-C12 alkyl(arylene), or substituted or unsubstituted aryl(C1-C12 alkylene). The hydrates and solvates of present invention also have surprisingly greater efficacy for delivering active agents, such as heparin and calcitonin, than their corresponding monosodium salts... Agent: Emisphere Technologies, Inc. C/o Darby & Darby P.C.

20100099609 - Eapp and derivatives for treatment of alzheimer's disease: This invention provides methods of reducing levels of amyloid beta (Aβ) protein and/or netrin-1 in a mammal. In certain embodiments the methods involve administering to the mammal a fragment of an amyloid precursor protein, or a mutant amyloid precursor protein, in an amount sufficient to decrease circulating levels of free... Agent: Weaver Austin Villeneuve & Sampson LLP

20100099618 - Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same: Chimeric polypeptide antagonists that include an interleukin-4 (IL-4) mutein linked to an interleukin-9 (IL-9) mutein are provided, as are polynucleotides encoding the IL-4 and IL-9 chimeric mutein antagonists. Also provided are methods of using the chimeric mutein antagonists and encoding polypeptides to reduce or inhibit the responsiveness of a cell... Agent: Dla Piper LLP (us)

20100099616 - Modified blood factors comprising a low degree of water soluble polymer: The present invention relates, in general, to materials and methods for the preparation of modified blood factors which have low levels of water soluble polymer molecules conjugated to the blood factor but exhibit biological activity similar to or better than molecules having a higher number of water soluble polymer moieties.... Agent: Marshall, Gerstein & Borun (baxter)

20100099619 - Pancreatic polypeptide family motifs, polypeptides and methods comprising the same: The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20100099615 - Pancreatic regenerating protein i in chronic pancreatitis and aging implications for new therapeutic approaches to diabetes: The present invention provides a method of treating diabetes, including administering to a mammal diagnosed with diabetes a purified recombinant reg I protein.... Agent: Hoffmann & Baron, LLP

20100099613 - Peptides for inducing a ctl and/or htl response to hepatitis c virus: The present invention is directed to peptides, and nucleic acids encoding them, derived from the Hepatitis C Virus (HCV). The peptides are those which elicit a CTL and/or HTL response in a host. The invention is also directed to compositions and vaccines for prevention and treatment of HCV infection and... Agent: Nixon & Vanderhye, PC

20100099620 - Protracted glp-1 compositions: Thixotropic compositions containing GLP-1 compounds have protracted action.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100099612 - Recombinant human interferon-like proteins: This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host... Agent: Oyen, Wiggs, Green & Mutala LLP 480 - The Station

20100099617 - Secreted proteins: The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.... Agent: Foley And Lardner LLP Suite 500

20100099610 - Transglutaminase variants with improved specificity: Variants of transglutaminase from Streptoverticillium ladakanum, which variants have improved selectivity for Gln-141 of human growth hormone are provided.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100099608 - Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor: Methods of treating a demyelinating disorder using inhibitors of the lymphotoxin pathway.... Agent: Lahive & Cockfield, LLP / Biogen Idec Floor 30, Suite 3000

20100099622 - Wound healing: The present invention relates to the use of p38 MAP kinase inhibitors and p38 MAP kinase inhibition to promote wound healing.... Agent: Morgan, Lewis & Bockius LLP

20100099627 - Nuclear targeting sequences: Isolated peptides comprising nuclear targeting activity or being capable of preventing endogenous nuclear targeting activity are disclosed. Polynucleotides encoding same, pharmaceutical compositions comprising same, as well as uses thereof are also disclosed.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100099626 - Cell penetrating peptides for intracellular delivery of molecules: The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX9WRAX9WRX1LX2RSLX9WX3X4X5X6X7X8 (SEQ ID No: 1), wherein X1 is A, L or G, X2 is W or none, X3 is R or K, X4 is K, L or S, X5 is L or K, X6 is R... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100099628 - Carbohydrate-based peritoneal dialysis fluid comprising glutamine residue: The present invention relates to a carbohydrate-based peritoneal dialysis fluid, containing a compound selected from the group consisting of glutamine, preferably L-glutamine, a dipeptide capable of releasing glutamine, L-glutamine in free form, preferably selected from the group consisting of glutaminyl-glycine, glycinyl-glutamine, glutaminyl-alanine, alanyl-glutamine an oligopeptide consisting of two to seven... Agent: Birch Stewart Kolasch & Birch

20100099629 - Ophthalmological composition: An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to opthalmological fields, and provide an opthalmological composition having this minimum unit as an effective component. This invention provides an opthalmological composition, in particular, a corneal disorder treatment agent... Agent: Burr & Brown

20100099630 - Method for improving ventilatory efficiency: This invention is a method of improving the function of the pulmonary arm of the cardiac-pulmonary axis by the administration of a pharmaceutical or nutritional supplement to a patient in which the function of the pulmonary arm is suboptimal, but not as a sequella of dysfunction of the cardiac arm.... Agent: Kathleen R. Terry

20100099631 - Novel use: The present invention relates to the use of the combined oral administration of caffeine with carbohydrate for increasing the rate of muscle glycogen resynthesis after strenuous exercise.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100099632 - Oligosaccharide aldonic acids and their topical use: Methods for using compositions comprising oligosaccharide aldonic acids for general care, as well as for treatment and prevention, of various cosmetic conditions and dermatological disorders, including those associated with intrinsic and/or extrinsic aging, as well as with changes or damage caused by extrinsic factors; general care, as well as treatment... Agent: Goodwin Procter LLP

20100099633 - Method for enhancing nutrient absorption with astragalosides: The present application relates to a method for enhancing absorption of a nutrient in a subject in need thereof with an effective amount of an isolated astragaloside compound.... Agent: Occhiuti Rohlicek & Tsao, LLP

20100099634 - Macrolide compounds endowed with antiinflammatory activity: The present invention relates to macrolide derivatives of formula (I) in which R1 and R2 have the meanings given in the description; which are endowed with antiinflammatory activity and are substantially free of antibiotic properties, to pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing them as active ingredient.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100099635 - Method for treating cystic fibrosis: The present invention is directed to a method for treating cystic fibrosis. The method comprises the steps of: identifying a patient suffering from cystic fibrosis, and administering to the patient an effective amount of denufosol or a pharmaceutically acceptable salt thereof and an effective amount of a macrolide. In one... Agent: Howery LLP

20100099636 - Hydrous gel and production process and use of the hydrous gel: A hydrous gel substantially comprising at least two polymers selected from the group consisting of polyacrylic acid, sodium polyacrylate and partially neutralized polyacrylate, and water, the polymers being crosslinked by containing an aluminum compound, wherein the pH when the hydrous gel is 100-fold diluted with purified water is from 6.5... Agent: Sughrue Mion, PLLC

20100099638 - Immunocompetent xenograft model: The teachings are directed to an immunocompetent xenograft model. The model comprises an immunodeficient animal modified to have a reconstituted immune system, wherein a xenograft is transplanted in the animal and allowed to establish for an establishment period of at least about 10 days. The xenograft simulates a tissue in... Agent: Brian S. Boyer, Ph.d.

20100099640 - Tissue degeneration protection: The present invention provides isolated or essentially pure diterpenoic tetrahydropyran, such as steviol-19-glucuronide, steviol, stevioside and rebaudioside processes for obtaining the same and methods for obtaining stable pharmaceutically acceptable salts of the same for use of such compounds or compositions in a treatment of cardiovascular disorders or vascular disease or... Agent: Traskbritt, P.C.

20100099637 - Use of cycloartane compounds for treating arthritis: A method of treating a disease associated with cartilage defect in a subject in need thereof by administering to the subject an effectively amount of a cycloartane compound of Formula (I).... Agent: Occhiuti Rohlicek & Tsao, LLP

20100099639 - W/o/w emulsion composition: The present invention provides a W/O/W multiple emulsion composition composed of an internal aqueous phase, an oil phase, and an external aqueous phase, the internal aqueous phase containing an ionic physiologically active substance and a physiologically acceptable compound having a molecular weight of 1,000 or less and generating a polyvalent... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100099641 - Crystalline form of 1-choloro-4-(beta-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments: The invention relates to a crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100099739 - Compositions and methods for gene silencing: Compositions and methods for modulating the expression of a protein of interest are provided.... Agent: Dann, Dorfman, Herrell & Skillman

20100099737 - Compositions and methods for treating myelosuppression: The invention provides, in part, compositions and methods for protecting a hemopoietic cell, or for treating myelosuppression, in a subject in need thereof, by administering an effective amount of an inhibitor of a SH2-containing inositol-5′-phosphatase.... Agent: Clark & Elbing LLP

20100099740 - Methods and compositions for rnai mediated inhibition of gene expression in mammals: Methods and compositions are provided for modulating, e.g., reducing, expression of a target sequence in mammals and mammalian cells in vivo. In the subject methods, an effective amount of an RNAi agent, e.g., an interfering ribonucleic acid (such as an siRNA or shRNA) is introduced into a target cell, e.g.,... Agent: King & Spalding LLP

20100099741 - Molecular targets for treatment of learning and memory dysfunction: Described herein are methods for identification of alternative safe molecular targets and novel regulators in complex molecular networks using a novel fault diagnosis engineering approach. For example, in this invention we claim new molecular targets that could be effectively targeted for changing the activity of CREB, and therefore for treatment... Agent: Mccarter & English, LLP Hartford Cityplace I

20100099738 - Polyethylene glycol lipid conjugates and uses thereof: Polyethylene glycol (PEG)-lipid conjugates, polyethylene glycol (PEG)-lipid conjugate based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20100099743 - Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating checkpoint kinase (e.g., checkpoint kinase-1 or CHK-1) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of... Agent: Merck And Co., Inc

20100099744 - Rna interference mediated inhibition of matrix metalloproteinase 13 (mmp13) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating matrix metalloproteinase (e.g., MMP13) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of MMP13 gene expression... Agent: Merck And Co., Inc

20100099742 - Sensitizing cells for apoptosis by selectively blocking cytokines: The invention refers to the use of a cytokine antagonist which modulates the expression and/or the function of a cytokine, particularly a Th2 helper cell cytokine, in a cell and causes the down-regulation of anti-apoptotic proteins in said cell through the cytokine modulation for sensitizing cells for apoptosis. In particular,... Agent: Townsend And Townsend And Crew, LLP

20100099745 - Enhancing disease resistance against rna viral infections with intracytoplasmic pathogen sensors: The present disclosure provides compositions and methods for enhancing resistance to viral infections. The compositions include adenovirus vectors containing nucleic acid molecules encoding CARD domains from RIG-I and MDA5, recombinant adenoviruses and immunogenic compositions comprising such recombinant adenovirus vectors and adenoviruses. Methods for enhancing resistance to viral infections involving administering... Agent: Klarquist Sparkman, LLP

20100099748 - Microrna molecules: In Caenorhabditis elegans, lin-4 and let-7 enclode 22- and 21-nucleotide RNAs, respectively, that function as key regulators of developmental timing. Because the appearance of these short RNAs is regulated during development, they are also referred to as “small temporal RNAs” (stRNAs). We show that many more 21- and 22-nt expressed... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100099746 - Novel nucleic acid: The present invention provides a nucleic acid such as a micro-RNA or a micro-RNA precursor, having a novel sequence. The nucleic acid of the present invention is useful for detecting the expression or a mutation of a micro-RNA, separating cells, suppressing the expression of a gene having a target sequence,... Agent: Leydig Voit & Mayer, Ltd

20100099749 - Nucleic acid inhibitors of glutamate receptors: The present invention relates to novel nucleic acid ligands or aptamers that bind to and inhibit the activation of the α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) subtype of ionotropic glutamate receptors. Also disclosed is a novel combination of technologies, i.e., SELEX and laser pulse photolysis for the selection and screening of aptamers that... Agent: Heslin Rothenberg Farley & Mesiti PC

20100099747 - Reduction of polyalanine-induced protein aggregates and toxicity by ubiquilin: A method for decreasing cell death in a cell exhibiting aggregation of polyalanine-containing proteins. The method includes introduction of an expression vector to a host cell comprising a nucleotide sequence encoding ubiquilin, followed by maintaining the transformed host cell under biological conditions sufficient for expression and accumulation of the ubiquilin... Agent: Intellectual Property / Technology Law

20100099750 - Rna interference mediated inhibition of muscarinic colinergic receptor gene expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods useful for modulating the expression of genes associated with respiratory and pulmonary disease, such as cholinergic muscarinic receptor genes, using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and... Agent: Merck And Co., Inc

20100099642 - Tgf-beta stimulant and further agent to reduce side effects: The invention relates to the use of TGF-beta stimulating agents, and in particular members of the triphenylethylene class of pharmaceutical agents, for the prevention, prophylaxis, treatment or amelioration of symptoms of cardiovascular disease, autoimmune diseases or neurodegeneration. In particular, improved compositions consisting of triphenylethylene agents combined with one or more... Agent: Schwegman, Lundberg & Woessner, P.A.

20100099643 - Fused pentacyclic polyethers: e

20100099644 - Hpma - docetaxel or gemcitabine conjugates and uses therefore: Disclosed are water-soluble compositions of gemcitabine and docetaxel formed by conjugating the gemcitabine or docetaxel to a water-soluble polymer such as N-2-hydroxypropyl methacrylamide (HPMA). Also disclosed are methods of using the compositions of the invention for the treatment of cancer.... Agent: Venable LLP

20100099645 - Compositions containing pufa and methods of use thereof: This invention provides methods of increasing or enhancing the synthesis and levels of phospholipids, synapses, synaptic proteins, and synaptic membranes by a neural cell or brain cell; methods of treating a subject with a memory disorder, memory impairment, neurological disorder, or brain disease or disorder, comprising administering to the subject... Agent: Pearl Cohen Zedek Latzer, LLP

20100099646 - W/o/w emulsion composition: A W/O/W emulsion composition having high emulsion stability, which can be prepared extremely easily and for which the production efficiency of the W/O/W emulsion product is favorable, and a method of producing such a W/O/W emulsion composition. The W/O/W emulsion composition of the present invention includes 0.001 to 60% by... Agent: Wood, Herron & Evans, LLP

20100099647 - Aqueous iron carbohydrate complexes, their production and medicaments containing them: Water soluble iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5... Agent: Rankin, Hill & Clark LLP

20100099648 - Natural equivalent of chemically modified starch: The present invention relates to a composition comprising citrus fruit fiber having a water binding capacity of from 8 to 25 (w/w) and native starch selected from the group consisting of corn starch, rice flour, sorghum starch, tapioca starch and mixture thereof.... Agent: Fish & Richardson P.C.

20100099649 - Site-specific chemical modification of proteins at their n-termini, enabling the formation of homogeneous adducts: Site-specific modifications of proteins at their N-termini are provided. In particular, a chemical modification of proteins at their N-termini via a transamination reaction to form homogeneous adducts such as, the corresponding oxime derivatives is provided. Methods of making and using the adducts in radio-labelling, molecular imaging applications, and treatment of... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100099650 - Nasal spray composition and method for treating rhinitis, sinusitis or both: A nasal spray composition for treating mucosal inflammation associated with rhinitis, sinusitis, or both can include a decongestant and at least one therapeutic agent. The therapeutic agent is selected from the group consisting of an anti-inflammatory agent and an anti-histamine agent. The nasal spray composition is non-habituating and is administered... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20100099652 - Novel composition based on cholest-4-en-3-one oxime: A subject of the invention is a novel composition, particularly a pharmaceutical composition comprising cholest-4-en-3-one oxime and an oil chosen from sesame oil, olive oil, soya oil, cotton oil, or a mixture of commercial medium-chain triglycerides (ESTASAN®, MYGLIOL®), or a mixture of these oils, preferably sesame oil, olive oil or... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100099651 - Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders: The present invention relates to novel pharmaceutical compositions comprising at least one EGFR kinase inhibitor and at least one additional active compound selected from beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK1 antagonists, anticholinergics and endothelin antagonists, processes for preparing the compositions and the use thereof as medicament... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100099653 - Particle size reduction apparatus, and use thereof: A sterilisable particle-size reduction apparatus, component parts thereof and a method of sterilising and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100099654 - Fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents: The present invention relates to certain unsaturated fatty acid derivatives of therapeutically active glucocorticoides-fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents and pharmaceutical formulations containing them.... Agent: Fitzpatrick Cella Harper & Scinto

20100099655 - Implants and methods for treating inflammation-mediated conditions of the eye: Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration... Agent: Allergan, Inc.

20100099656 - Neurotherapeutic compositions: Novel neuroprotectant compositions and methods are described. (β-Lactamase inhibitors are used to prevent or reduce loss of neuronal cells and neuronal cell function in patients afflicted with or susceptible to disease states or conditions known to result in or cause neuronal tissue insult.... Agent: Barnes & Thornburg LLP

20100099657 - Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity: Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.... Agent: Pepper Hamilton LLP

20100099659 - Inhibitors of bruton's tyrosine kinase: wherein, variables R, X, Y1, Y2, Y3, Y4, n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100099660 - Method for treating thrombosis or embolism and related diseases: A method for treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100099661 - Antibacterial aminoglycoside analogs: m

20100099658 - Di(arylamino)aryl compound: As a result of extensive and intensive studies on compounds having an inhibitory effect against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins, the inventors of the present invention have found that the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of... Agent: Nixon & Vanderhye, PC

20100099662 - Hydrazone derivative:

20100099663 - 4-trifluoromethoxyphenoxybenzol-4'-sulfonic acids, method for the production and use thereof in medicaments:

20100099664 - Substituted pyrrolidine amides, the production thereof, and the use thereof as medications: The object of the present invention is novel substituted pyrrolidine amides of the general formula (I) in which D, L. E, G, J, M, L1, L2, R4, and R5 are defined as in the specification, the tautomers, enantiomers, diastereomers, mixtures, and salts thereof, particularly physiologically tolerated salts with inorganic or... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100099665 - Isoquinolinone derivatives: e

20100099666 - Phenothiazine modulators of h1 receptor and d2 receptor: The present invention relates to new phenothiazine modulators of H1 receptors and/or D2 receptors, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100099667 - Bridged heterocyclic compounds and methods of use: This disclosure relates to new compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new bridged heterocyclic [4,3-b]indole compounds. Pharmaceutical compositions are also provided. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a... Agent: Morrison & Foerster LLP

20100099668 - Local topical administration formulations containing indoxacarb: The present invention provides formulations and methods useful in the control of ectoparasites on a domestic animal, using a formulation comprising Indoxacarb and a veterinarily acceptable carrier that is applied topically to 10% or less of the total surface area of a domestic animal. Other embodiments include these formulations also... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20100099669 - Dopamine 3 receptor agonist and antagonist treatment of gastrointestinal motility disorders: Provided herein are methods of treating gastrointestinal motility disorders by targeting the dopamine 3 receptor (D3R). A D3R agonist is administered to a subject to decrease gastrointestinal motility to treat the disorder. A D3R antagonist is administered to a subject to decrease gastrointestinal motility to treat the disorder.... Agent: Benjamin Aaron Adler Adler & Associates

20100099670 - Benzoquinazoline derivatives: o

20100099671 - Glucokinase activator: (wherein, the carbon atom marked with an * is in the R-configuration, R1 represents a hydrogen atom, a halogen atom, an amino group, a hydroxyl group, a hydroxyamino group, a nitro group, a cyano group, a sulfamoyl group, a C1-C6 alkyl group, or a C1-C6 alkoxy group, R2 represents a... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100099672 - Methods for treating hepatitis c: In accordance with the present invention, compounds that can inhibit viral replication, preferably Hepatitis C Virus (HCV) replication, have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the treatment or prevention of a viral infection are provided. In another aspect of... Agent: Hoffmann & Baron, LLP

20100099673 - Decahydroquinoline analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases: The present invention relates to compounds represented by Formula (I): and pharmaceutically acceptable salts thereof. The present invention also provides pharmaceutical compositions comprising the instant compounds. This invention further provides methods to treat and prevent pain, respiratory and non-respiratory diseases.... Agent: Merck And Co., Inc

20100099674 - Method and means for preventing and inhibiting type iii secretion in infections caused by gram-negative bacteria: A means for decreasing bacterial virulence in a mammal including man or in a plant by inhibition of the Type III secretion system at concentrations that do not prevent or substantially reduce bacterial growth comprises an N-substituted 7-quinolylmethyl amine, in particular one that is further substituted in 5- and 8-position... Agent: Dickstein Shapiro LLP

20100099675 - Novel pyrrole derivative having ureido group and aminocarbonyl group as substituents: Objects of the present invention are to study on the synthesis of a novel pyrrole derivative having a ureido group and an aminocarbonyl group as substituents or a salt thereof, to find a pharmacological effect of the derivative or a salt thereof, and to find a medicinal agent which has... Agent: Frishauf, Holtz, Goodman & Chick, PC

20100099676 - Sulfonylurea derivative capable of selectively inhibiting mmp-13: wherein R6 and R7 are each independently lower alkyl and the like; m and n are each independently 0, 1, or 2; R2 is a hydrogen atom and the like; R3 is optionally substituted lower alkyl and the like; R4 is a hydrogen atom; or R3 and R4 may be... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100099677 - Compounds, compositions and methods comprising thiazole derivatives: The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set... Agent: Foley & Lardner LLP

20100099678 - Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders: The present embodiments are related to the compound of Formula 1 or Formula 2 below and pharmaceutical formulations thereof as well as treatments for a wide variety of Central Nervous System disorders with the pharmaceutical formulations. Some embodiments include the use of a variety of the instant compounds which surprisingly... Agent: Knobbe Martens Olson & Bear LLP

20100099679 - Fused bicyclic mtor inhibitors: e

20100099682 - Acetylene derivatives:

20100099683 - Compounds that inhibit human dna ligases and methods of treating cancer: Methods for treating cancer using compounds that inhibit human DNA ligases. Methods for using compounds that inhibit human DNA ligases to provide insights into the reaction mechanisms of human DNA ligases, for example to identify the human DNA ligase involved in different DNA repair pathways. Screening methods for compounds that... Agent: Miles & Stockbridge PC

20100099685 - Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride: Crystal forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride, hydrates and solvates and processes for their preparation are provided. These crystal forms are either intermediates for the preparation of stable polymorphic form B or are suitable for solid formulations.... Agent: Millen, White, Zelano & Branigan, P.C.

20100099680 - Pteridinone derivatives as p13-kinases inhibitors: New compounds of Formula (1) are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastro-intestinal tract and motor apparatus,... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100099684 - Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100099681 - Substituted 5-aminopyrazoles and use thereof: The present application relates to novel substituted 5-aminopyrazoles, methods of production thereof, use thereof alone or in combinations for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100099686 - Compounds useful as protein kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz And Cohn

20100099687 - Tadalafil solid composites: This invention relates to oral pharmaceutical compositions suitable for making pharmaceutical formulations for oral administration that provide for the rapid dissolution of the phosphodiesterase 5 inhibitor tadalafil. In particular, the pharmaceutical compositions comprise solid composites of tadalafil exhibiting high solubility and rate of dissolution. The invention further relates to methods... Agent: Kenyon & Kenyon LLP

20100099688 - Novel phosphodiesterase inhibitors: wherein X, A, G, E, R1, R2, R3 are as shown herein; and pharmaceutically acceptable salts, hydrates, N-oxides or solvates hereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and... Agent: Birch Stewart Kolasch & Birch

20100099689 - Methods of modulating ppar gamma-type receptors: e

20100099690 - Xanthine derivatives as selective hm74a agonists: The present invention relates to compounds which are xanthine derivatives, processes for the manufacture of said derivatives, pharmaceutical formulations containing the active compounds and the use of the compounds in therapy, for example, in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100099691 - Pyrimidinyl pyridone inhibitors of jnk: wherein R1, R2, and R3 are defined as described herein, which inhibit JNK. The compounds disclosed herein are useful to modulate the activity of JNK and treat diseases associated with excessive JNK activity. The compounds are useful to treat autoimmune, inflammatory, metabolic, and neurological diseases as well as cancer. Also... Agent: Grant D. Green Patent Law Department ,

20100099692 - Harmful organism control composition: e

20100099694 - 2-anilino-4-heteroaryl pyrimidine derivatives, and preparation thereof as medicaments, pharmaceutical compositions, and in particular ikk inhibitors:

20100099693 - New combination for use in the treatment of inflammatory disorders: There is provided combination products comprising (a) ramatroban, or a pharmaceutically-acceptable salt or solvate thereof and (b) a statin, or a pharmaceutically-acceptable salt or solvate thereof. Such combination products find particular utility in the treatment of atherosclerosis and related conditions.... Agent: Ryan Kromholz & Manion, S.c.

20100099695 - Hcv ns3 protease inhibitors: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.... Agent: Merck And Co., Inc

20100099696 - Tamper resistant oral dosage forms containing an embolizing agent: Oral dosage form containing a therapeutically effective amount of a drug susceptible to abuse and an effective amount of an embolizing agent which causes the production of a solid or semi-solid embolus or blockage after tampering.... Agent: Howard Eisenberg, Esq.

20100099697 - Method of treatment using inhibitors of mitosis: Methods of treating diseases caused by cell division or that are treated by inhibiting mitosis by administering two doses of an inhibitor of mitosis between the biologically effective dose and the maximum tolerated dose in a dosing cycle that allows for the recovery or subsiding of side effects, wherein the... Agent: Viksnins Harris & Padys Pllp

20100099698 - Compositions for improving skin conditions comprising matrine or its oxidized derivatives: The present invention relates to a composition for improving skin conditions comprising matrine and oxymatrine as an active ingredient. Matrine and oxymatrine have lower cytotoxicity than retinol used as anti-wrinkle agents and exhibit the inhibition effect on collagenase activity and promotion effect on collagen biosynthesis at a molecular level, contributing... Agent: Clark & Elbing LLP

20100099699 - Peripheral opioid receptor antagonists and uses thereof: e

20100099700 - Hydrogenated pyrido (4,3-b) indoles for treating amyotrophic lateral sclerosis (als): The invention provides methods for treating and/or preventing and/or slowing the onset and/or development of ALS using hydrogenated pyrido(4,3-b)indoles, such as dimebon.... Agent: Morrison & Foerster LLP

20100099701 - Isoquinolinone modulators of 5-ht3 receptors: The present invention relates to new isoquinolinone modulators of 5-HT3 receptors, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100099702 - Therapeutic agent for neuropathic pain: Disclosed is a therapeutic agent for neuropathic pain having an excellent therapeutic effect on neuropathic pain which is a intractable disease. More specifically, disclosed are a therapeutic agent for neuropathic pain which comprises a peripheral benzodiazepine receptor antagonist (particularly PK 11195) as the active ingredient; a pharmaceutical composition for the... Agent: Foley And Lardner LLP Suite 500

20100099703 - Phenylamino-substituted piperidine compounds, their preparation and use as medicaments: The present invention relates to phenylamino-substituted piperidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans or animals.... Agent: Quarles & Brady LLP

20100099705 - Argatroban formulation: An aqueous, stable, sterile pharmaceutical composition of the thrombin inhibitor argatroban in a solution containing an acid to solubilize the argatroban, substantially free from dehydrated alcohol is described, as well as a method for its preparation.... Agent: K&l Gates LLP

20100099706 - Argatroban formulation: An aqueous, stable, sterile pharmaceutical composition of the thrombin inhibitor argatroban in a solution containing an acid to solubilize the argatroban, substantially free from dehydrated alcohol is described, as well as a method for its preparation.... Agent: K&l Gates LLP

20100099704 - Lotion preparation containing pyridonecarboxylic acid derivative: It is intended to provide a lotion preparation which exerts an excellent antibacterial effect, is excellent in the stability of active ingredient and does not contain an additive having a safety problem. The lotion preparation contains (a) 1-cyclo-propyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid and/or a pharmaceutically acceptable salt thereof, (b) a lower alcohol, (c)... Agent: Kirschstein, Israel, Schiffmiller & Pieroni, P.C.

20100099707 - Method for treating pulmonary arterial hypertension: Pulmonary arterial hypertension in a mammal can be prevented or treated using combined 5-HT2A and 5-HT2B receptor antagonist. The antagonists can be present in a single compound or in two separate compounds... Agent: Ladas & Parry LLP

20100099708 - Piperidine derivative used for treating chemokine receptor 5 mediated diseases: The present invention relates to 4-[3-(1,1-difluoroethyl)-5-methyl-4H-1,2,4-triazol-4-yl]-1-{(1R,3R)-3-(3,5-difluorophenyl)-1-methyl-3-[1-(methylsulfonyl)ρiperidin-4-yl]propyl}piperidine formula (I): or a pharmaceutically acceptable salt thereof, as well as processes for the preparation of this compound and its use in the treatment of CCR5 disease states.... Agent: Fish & Richardson P.C.

20100099709 - Pyridin-2-yl-methylamine derivatives for treating opiate dependence: e

20100099710 - Src family kinase inhibitors: The invention relates to compounds of general formula (I) wherein X, A, R1 and R2 are as defined herein for use as antiinflammatory agents capable of modulating the activity of a protein tyrosine kinase of the Src family.... Agent: Birch Stewart Kolasch & Birch

20100099711 - Methods and compositions using immunomodulatory compounds for the treatment and management of cancers and other diseases: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or... Agent: Jones Day

20100099712 - Substituted pyrazoline compounds with acat inhibition activity: The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals, especially in dyslipidaemia.... Agent: Heslin Rothenberg Farley & Mesiti PC

20100099713 - 2-aminopyridine derivatives as glucokinase activators: or salts thereof, wherein R2, L, R3, R11, D2 and R13 are as defined herein, that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity... Agent: Viksnins Harris & Padys Pllp

20100099714 - Ampa and nmda receptor antagonists for neurodegenerative diseases: The invention provides methods for treating, preventing, and delaying the onset of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, Pick's disease, and the like), dementia, mild cognitive impairments, glaucoma, ocular hypertension, and pain (e.g., neuropathic pain, headaches, and the like) by administering therapeutically... Agent: Clark & Elbing LLP

20100099715 - 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mglur2-receptor modulators: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) including any stereochemically isomeric form thereof, or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein all radicals are defined in the application and claims. The compounds according to the invention are positive... Agent: Gardner Groff Greenwald & Villanueva. PC

20100099716 - Cetp inhibitors: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring... Agent: Merck And Co., Inc

20100099717 - Suspension concentrates for improving the root absorption of agrochemical active ingredients: It is possible to increase the uptake of active compounds from crop protection compositions using suitable adjuvants, and thus to improve the action of crop protection agents. The present invention describes suitable adjuvants, methods and compositions.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100099718 - Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same: wherein R1 represents a hydrogen atom, a halogen atom, an amino group, a C1-6 alkyl group, a C1-6 alkoxy group, or a C1-6-alkoxy-C1-6-alkyl group; R2 represents a hydrogen atom or an amino group; X, Y, Z, and W independently represent a nitrogen atom, an oxygen atom, a sulfur atom, or... Agent: Birch Stewart Kolasch & Birch

20100099719 - Composition and method for treating proteinuria: The present invention discloses 5-methyl-1-(substituted phenyl)-2(1H)-pyridones having the ability to reduce proteinuria and for treating kidney diseases. The ability to reduce proteinuria has a renoprotective effect for slowing the progression of kidney diseases. A representative example of 5-methyl-(1-substituted phenyl)-2(1H)-pyridones is 1-(3′-fluorophenyl)-5-methyl-2(1H)-pyridone, AKF-PD. Accordingly, the present invention provides compositions comprising one... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20100099720 - Gene polymorphisms as sex-specific predictors in cancer therapy: The invention provides compositions and methods for determining the likelihood of gender-specific successful treatment with 5-FU/oxaliplatin or an equivalent of each thereof. The methods comprise determining the genomic polymorphism present in a predetermined region of a gene of interest and correlating the polymorphism to the predictive response. Patients identified as... Agent: Foley & Lardner LLP

20100099721 - Novel compounds for the treatment of neurological disorders: e

20100099722 - 2-(benzimidazol-1-yl)-n-(4-phenylthiazol-2-yl) acetamide derivatives: wherein R1 is H, (C1-4)alkyl, (C1-4)alkyloxy or halogen; R2 represents 1-3 substituents selected from H, (C1-4)alkyl (optionally substituted with 1 or more halogens), (C1-4)alkyl-oxy (optionally substituted with 1 or more halogens), halogen, CF3 or cyano; or a pharmaceutically acceptable salt thereof; to pharmaceutical compositions comprising the same and to the... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20100099723 - Bioavailable compositions of metaxalone and processes for producing the same: Pharmaceutical compositions comprising metaxalone which demonstrate improved dissolution and bioavailability characteristics compared to the commercially available product, and methods of producing them are provided. In a preferred embodiment, a dosage form comprising metaxalone and at least one inactive powder excipient is bioequivalent to its commercially available counterpart (Skelaxin® 400-mg tablets)... Agent: Cantor Colburn, LLP

20100099724 - Formulations comprising triazoles and alkoxylated amines: The present invention relates to the use of alkoxylated amines to enhance the activity of fungicidal formulations comprising fungicidal triazoles. It also relates to formulations comprising one or more fungicidal triazoles and alkoxylated amines. These formulations are useful for the protection of any living or non-living material, such as crops,... Agent: Woodcock Washburn LLP

20100099725 - Peroxisome proliferator activated receptor modulators: The present invention is directed to compounds of the structural Formula: wherein: R1 is H or —C1-C3 alkyl; R2 is selected from the group consisting of —H, —C1-C4 alkyl, —C1-C3 alkyl-CF3, phenyl, and pyridinyl; and R3 is selected from the group consisting of —H, —C1-C4 alkyl, —C1-C3 alkyl-O—CH3, —CH2-cyclopropyl, CH2—C═CH2,... Agent: Eli Lilly & Company

20100099726 - Inhibitors of pyruvate kinase and methods of treating disease: The invention provides pharmaceutical compositions, kits, and methods of treating cancer, diabetes, obesity, autoimmune disease, and benign prostatic hyperplasia using compounds that selectively inhibit pyruvate kinase M2 and an assay measuring chemical modulation of pyruvate kinase activity.... Agent: Clark & Elbing LLP

20100099727 - Amino acid and peptide conjugates of arylalkylic acids for cosmetic use: e

20100099728 - Spiro-oxindole compounds and their use as therapeutic agents: This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.... Agent: SeedIPLaw Group PLLC

20100099729 - Nitric oxide donor compounds: The invention relates to nitric oxide donor compounds and their use for treating cardiovascular diseases, inflammation, pain, fever, gastrointestinal disorders, ophthalmic diseases, hepatic disorders, renal diseases, respiratory disorders, immunological diseases, bone metobolismsdysfunctions, central and peripheral nervous system diseases, sexual dysfunctions, infectious diseases, for the inhibition of platelet aggregation and platelet... Agent: Arent Fox LLP

20100099730 - Annellated pyrrole compounds for cancer management: The present invention relates to the use of annellated pyrrole compounds and in particular ML3000 (licofelone), salts or derivatives thereof, for cancer management, and in general to the use of a compound of Formula (I): wherein the variables have the meanings given in the present description, for the prevention and/or... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100099731 - Use of endothelial interrupters in the treatment of neurodegenerative diseases: In various embodiments, the present invention relates generally to methods of treating at least one neurodegenerative disease by administering a medicament comprising an endothelial interrupter.... Agent: Roman Aguilera Iii Ttus Office Of Technology Commercialization

20100099732 - Medicaments useful as potassium channel modulators: This invention relates to pharmaceutical compositions comprising phenylcarbamoyl-methyl-indole derivatives that are found to be potent modulators of potassium channels and, as such, are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to the modulation of potassium channels.... Agent: Birch Stewart Kolasch & Birch

20100099733 - Method for obtaining a stable dispersion of benzoyl peroxide: Powder containing benzoyl peroxide is readily wetted by contacting the powder with a liquid containing one or more of a polyol, a polyol ether, and a low-carbon organic alcohol.... Agent: Howard Eisenberg, Esq.

20100099734 - Amino acid and its uses: This invention relates to a supplement, the use thereof and method for supplementing the concentration of free cellular L-proline in an organism, for restricting dehydration of such an organism, the supplement comprising an effective amount of free L-proline. The supplement is effective in reducing the levels of free radicals in... Agent: Schwegman, Lundberg & Woessner, P.A.

20100099735 - Methods and compositions for improving cognitive function: This invention relates to treating age-related cognitive impairment. This invention in particular relates to the use of inhibitors of synaptic vesicle protein 2A (SV2A), such as levetiracetam, seletracetam, and brivaracetam, in improving cognitive function in subjects that exhibit age-related cognitive impairment or are at risk thereof, including, without limitation, subjects... Agent: Ropes & Gray LLP

20100099736 - Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting mpt: The invention discloses the use of a compound of formula (I), wherein R1, R2, R3, and R4 each independently represents: hydrogen; halo; hydroxy; (C1-C6) alkyl optionally substituted by hydroxy or (C1-C4) alkoxy; (C1-C6) haloalkyl; (C1-C6) alkoxy; and (C1-C6) haloalkoxy; for the preparation of a medicament for the prevention and/or treatment... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100099751 - Method of treating diabetes-related vascular complications: A method of treating diabetes-related vascular complications is provided. It has been found that a heightened state of oxidative stress, either acting alone or in concert with augmented apoptotic and inflammatory processes, contributes to diabetes-related vascular dysfunction. The method of treating diabetes-related vascular complications includes the treatment of diabetic patients... Agent: Litman Law Offices, Ltd.

20100099752 - Pharmaceutical composition containing bicyclic type compounds: The present invention relates to pharmaceutical compositions containing bicyclic type compounds and to methods of using same, for example, in the treatment or prevention of anxiety, mania, depression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse, Parkinson's Disease, psychosis, migraine... Agent: Nixon & Vanderhye, PC

20100099753 - Dietary and pharmaceutical compositions containing tricyclic diterpenes and their derivates and their uses: The present invention refers to tricyclic diterpenes and their derivatives of the formulae (I) and (II), wherein R1 is hydrogen or C1-6-alkyl; R2 is hydroxy, C3-5-acyloxy, hydroxymethyl, 1,3-dihydroxypropyl or C1-6-alkyl; R3 and R4 independently from each other are hydrogen, hydroxy, hydroxymethyl, C1-5-acyloxy or C1-6-alkoxy; R5 is C1-6-alkyl, hydroxymethyl carboxy or... Agent: Nixon & Vanderhye, PC

20100099754 - 5,6-dimethyl xanthone-4-acetic acid derivatives and method of preparing the same: A method of preparation of 5,6-dimethylxanthone-4-acetic acid (DMXAA) and derivatives thereof. The derivatives are represented by formula (I), wherein R represents totally 1 to 2 substitutes at 1, 2, 3, 7, and 8 position selected from a lower alkyl, halogen, CF3, CN, NO2, NH2, CH2COOH, OR2, OH, NHSO2R2, SR2, CH2CONHR2... Agent: Matthias Scholl

20100099755 - Chemotherapeutic flavonoids, and syntheses thereof: Substituted flavonoid compounds, and pharmaceutical formulations of flavonoid compounds are described. Also described are processes for preparing flavonid compounds, as are methods for treating cancer in mammals using the described flavonoid compounds or pharmaceutical formulations thereof.... Agent: Barnes & Thornburg LLP

20100099756 - Uses of incensole, incensole acetate and derivatives thereof: The described subject matter relates to the use of incensole, incensole acetate, and derivatives thereof, for the treatment, prevention or amelioration of diseases or conditions, including inflammatory-associated conditions; a disease or condition where neuroprotection is required; and a disease or condition selected from depression, anxiety, obsessive compulsive behaviors, deterioration in... Agent: The Nath Law Group

20100099757 - Disulfiram doses and treatment regimen suitable for treatment of angiogenesis-dependent disorders: A pharmaceutical composition is provided. The pharmaceutical composition includes an amount of disulfuram in unit dosage form which results in a peak serum concentration level which is therapeutically effective in treating an angiogenesis-dependent disorder and can also exhibit minimal or no disulfuram related side effects.... Agent: Fennemore Craig

20100099759 - Agricultural applications of silver dihydrogen citrate: A method for treating a plant, the method comprising contacting a composition comprising silver dihydrogen citrate with at least one of the plant, a portion of soil and/or groundwater proximal to the plant, or a combination thereof.... Agent: Morrison & Foerster LLP

20100099758 - Regenerative wound healing using copper-silver citrate composition: A composition containing copper and silver ions electrolytically generated in a solution of citric acid that also contains potassium carbonate is shown to expedite the healing of wounds with regeneration of normal tissue architecture and without excessive scarring. A wide range of wounds and other forms of tissue damage affecting... Agent: William John Martin

20100099760 - Glycyrrhetinic acid derivatives: The present invention relates to novel derivatives of glycyrrhetinic acid, compositions comprising said derivatives and their use in the treatment of conditions or diseases that benefit from an upregulation of PPAR&ggr; and/or a downregulation of the expression or activity of one or more specificity (Sp) proteins, such as cancer, diabetes... Agent: Ballard Spahr LLP

20100099761 - Levodopa prodrug mesylate hydrate: Crystalline (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate, hydrate, methods of making the hydrate, pharmaceutical compositions containing the hydrate, and methods of using the hydrate to treat diseases or disorders such as Parkinson's disease are provided.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100099762 - Combination therapy: The present invention relates generally to a method of treating a psychiatric or neuropsychiatric condition in a mammal with a combination therapy. More particularly, the present invention relates to a combination therapy comprising an antipsychotic agent and a compound that increases levels of glutathione in the body.... Agent: Seed Intellectual Property Law Group PLLC

20100099763 - Triterpene compounds which are effective on improvement of brain function: The present invention relates to the triterpene compounds improving in brain functions. In particular, the present invention relates to a novel use of the triterpene compounds represented by the Formula 1 for improving decreased memory and a pharmaceutical composition for improving brain functions comprising the triterpene compounds represented by the... Agent: Frommer Lawrence & Haug

20100099764 - Production of arachidonic acid in oilseed plants: Oilseed plants which have been transformed to produce arachidonic acid, recombinant constructs used in such transformations, methods for producing arachidonic acid in a plant are described and uses of oils and seeds obtained from such transformed plants in a variety of food and feed applications are described.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100099765 - Compositions, methods, and kits for polyunsaturated fatty acids from microalgae: The present invention provides compositions, methods, and kits comprising PUFAs produced by microalgae, in particular omega-3 and/or omega-6 fatty acids produced by members of the genus Rhodomonas, in particular Rhodomonas salina. The invention also provides compositions, methods, and kits comprising the PUFAs for the prophylactic and/or therapeutic treatment of a... Agent: Womble Carlyle Sandridge & Rice, PLLC

20100099766 - Topical nsaid compositions having sensate component: Topical analgesic compositions comprising a topically administrable NSAID, a sensate agent and optionally a self-warming system, when administered to a patient in need thereof, provide significant improvements in the rate and extent of skin absorption, as well as impart a sensation of rapid and complete relief from pain.... Agent: Frank A. Smith Novartis Consumer Health, Inc.

20100099767 - Topical pharmaceutical formulation: A composition for topical application of an NSAID comprises a solution or suspension of the NSAID in a carrier system comprising a polyhydric alcohol, a glycol ether and an ester of A higher fatty acid, the carrier system being present as a single phase at ambient temperatures. The NSAID may... Agent: Morgan Lewis & Bockius LLP

20100099768 - 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases: 1-Phenylalkanecarboxylic acid derivatives, the processes for the preparation thereof and the use thereof in the treatment and/or prevention of neurodegenerative diseases such as Alzheimer's disease.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100099769 - Benzylamine derivative or pharmaceutically acceptable acid addition salt thereof, and use thereof for medical purposes: The benzylamine derivative represented by the formula below and a pharmaceutically acceptable acid addition salt thereof, and a pharmaceutical containing the derivative or the pharmaceutically acceptable acid addition salt thereof, and a therapeutic or prophylactic agent for pollakiuria or urinary incontinence containing the derivative or the pharmaceutically acceptable acid addition... Agent: Ip Group Of Dla Piper LLP (us)

20100099770 - Method for treating diabetic peripheral neuropathic pain: The present invention concerns the novel use of compounds of the Formula I: for treating allodynia as major and unique pain symptom independent of the nature of an underlying disease, but that is often related to neuropathic pain or other different types of chronic or phantom pain.... Agent: Harness, Dickey, & Pierce, P.l.c

20100099771 - Use of cooling agents to relieve mild ocular irritation and enhance comfort: Ophthalmic compositions containing very low concentrations (e.g., 1 to 50 ppm) of cooling agents are described. The cooling agents are less volatile and less prone to causing ocular discomfort than agents previously utilized to obtain an ocular cooling effect, such as menthol. The cooling agents are preferably contained in a... Agent: Alcon

20100099772 - Methods, compositions, and kits for treating pain and pruritis: The invention features a method for inhibiting one or more voltage-gated ion channels in a cell by contacting the cell with (i) a first compound that activates a channel-forming receptor that is present on nociceptors and/or pruriceptors; and (ii) a second compound that inhibits one or more voltage-gated ion channels... Agent: Clark & Elbing LLP

20100099773 - Inclusion complex of sibutramine and beta-cyclodextrin: The present invention relates to a sibutramine-containing inclusion complex having superior storage stability, and particularly to a pharmaceutically stable inclusion complex suitable for the drug formulation, which prepared by reacting a sibutramine (N,N-dimethyl-1-[1-(4-chlorophenyl)-cyclobutyl]-3-methylbutylamine) of Formula 1 and beta-cyclodextrin in a predetermined ratio, its preparation method and a pharmaceutical composition comprising... Agent: Frommer Lawrence & Haug

20100099774 - Method for controlling harmful fungi: The present invention relates to a method for controlling phytopathogenic fungior harmful fungi in the protection of materials, wherein the fungi or the materials, plants, soil or seed to be protected against fungal attack are treated with a fungicidally effective amount of an amidrazone of the formula (I) wherein R,... Agent: Brinks, Hofer, Gilson & Lione

20100099775 - Method for ameliorating of post-anesthetic recovery: The invention describes use of injectable form of Idebenone to improve recovery after general anesthesia and of cognitive functions, suppress disorientation and other signs of neuronal damage.... Agent: Alpharx Inc.

20100099776 - Oily suspension of atovaquone: The present invention relates to an oily suspension of atovaquone comprising atovaquone particles and a combination of surfactants having HLB more than 10.... Agent: Ranbaxy Inc.

20100099777 - Cinnamaldehyde - allicin compositions and their method of use: The invention generally relates to mixtures of cinnamaldehyde (cinnamic aldehyde) and allicin (10%) in emulsifiable suspension formulations at ratios ranging from 1:1 to 20:1 for protecting plants from damage by nematodes, fungal pathogens, insects and mites. The nematicidal compositions described are easily flowable, easily mixable in water and have low... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100099778 - Device and method for producing therapeutic foam: A device and a method for generating therapeutic foam from a sclerosing solution such as polidocanol and a gas which is absorbable or dissolvable in the body comprises a disposable cassette including a liquid container and a flexible chamber containing gas, chamber being formed as a loop. Located in the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100099779 - Biocompatible material composition adaptable to diverse therapeutic indications: A kit for forming a biocompatible material provides a protein solution and a polymer solution including a derivative of a hydrophilic polymer with a functionality of at least three. Upon mixing. the protein solution and the polymer solution cross-link to form a non-liquid, three-dimensional network that degrades over time back... Agent: Pepper Hamilton LLP

  
04/15/2010 > patent applications in patent subcategories. category listing, related patent applications
  
04/08/2010 > patent applications in patent subcategories. category listing, related patent applications

20100087358 - Notch mutations leading to increased receptor signaling: The present invention is based upon the identification of regions within the NOTCH-1 receptor that, when mutated, lead to increase receptor signaling. The mutations are associated with uncontrolled cellular growth and this growth may be arrested using agents that interfere with NOTCH-1 activity, such as inhibitors of gamma-secretase. Assays for... Agent: Law Office Of Michael A. Sanzo, LLC

20100087359 - Use of tryptophan rich peptides: The novel use of peptides derived from whey protein hydrolysate as active ingredient in a medicament or as food ingredient for elevating the cholescystokinin level in the blood, and for preventing or treatment of overweight and/or obesity, in an animal, including human, in need thereof.... Agent: Foley And Lardner LLP Suite 500

20100087360 - Heterocycle-substituted benzimidazole derivative: A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: (I) wherein X1 to X4 independently represent a carbon atom or the like; the ring A represents a 5- to 6-membered heteroaryl having 1 to 4 heteroatoms independently selected from the group consisting of a nitrogen atom,... Agent: Merck And Co., Inc

20100087361 - Method to enhance hemodynamic stability using oxygen carrying compositions: The present invention relates to methods for enhancing the hemodynamic stability of an individual undergoing surgery by administering a composition comprising a hemoglobin-based oxygen carrier. In one embodiment, the present invention relates to the use of polyalkylene oxide modified hemoglobins with reduced cooperativity and a high oxygen affinity to enhance... Agent: The Nath Law Group

20100087363 - Glycan modified soluble receptors and binding protein and their use: An invention relates to a glycan-modified soluble receptor or binding protein of a cytokine, growth factor, lipoprotein or oxidized lipoprotein, modified to carry a terminal Gal, GlcNAc or GalNAc.... Agent: Marshall, Gerstein & Borun LLP

20100087362 - Use of biglycan or enhancers of biglycan activity in the preparation of pharmaceutical compositions: The present invention relates to the use of biglycan or enhancers of biglycan activity in the preparation of pharmaceutical compositions having anti-atherosclerotic and anti-ischemic effect, and to the use of them in methods for preventing and treating the atherosclerotic and ischemid (e.g. cardiac) diseases. The invention also relates to screening... Agent: Leon R. Yankwich

20100087364 - Tropine modulators of 5-ht3 receptor: The present invention relates to new tropine modulators of 5-HT3 receptor, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100087376 - Cancer related isoforms of components of transcription factor complexes as biomarkers and drug targets: The invention is related to isoforms of components of transcription factor complexes that are specifically expressed in cancer cells. These isoforms can be used as biomarkers for detection, diagnosis, prognosis and monitoring of treatments of cancer, and as drug targets of pharmaceutical compositions for the treatment of various cancers expressing... Agent: Karen S. Canady Canady & Lortz LLP

20100087369 - Composition comprising oligogalacturonans and polycationic saccharides: A ‘bioactive’ composition that has one or more oligogalacturonans ((1→4)-α-D-galacturonan) or any other oligosaccharides (oligoguluronans) that may present an ‘egg box’ conformation, this conformation being further stabilized by one or more polycationic saccharide(s), preferably either a chitosan oligosaccharide or a chitosan polysaccharide. A method prepares this composition and it is... Agent: Merchant & Gould PC

20100087378 - Compositions and methods for treating diseases associate with angiogenesis and inflammation: Pharmaceutical compositions and methods for treating diseases associated with angiogenesis and inflammation. The invention relates to a pharmaceutical composition that includes a therapeutically effective amount of sCD26 and/or a biologically active derivative thereof and a pharmaceutically acceptable carrier. The composition may further include a therapeutically effective amount of sFlt-1 and/or... Agent: Wang Law Firm, Inc.

20100087377 - Compositions and methods to prevent cancer with cupredoxins: The present invention relates to compositions comprising peptides that may be variants, derivatives and structural equivalents of cupredoxins that inhibit the development of premalignant lesions in mammalian cells, tissues and animals. Specifically, these compositions may comprise azurin from Pseudomonas aeruginosa, and/or the 50-77 residue region of azurin (p28). The present... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20100087373 - Detection and therapy of bacterial infection caused by enterobacteriaceae: The present invention provides a method for the treatment and/or prevention of bacterial infection caused by Enterobacteriaceae bacteria in central nervous system and/or peripheral blood circulation in a mammal by administering effective amount of outer membrane protein A (OmpA) or its derivatives to a mammal. Also provided are a method... Agent: Wpat, PC Intellectual Property Attorneys

20100087366 - Gh secretagogues and uses thereof: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime... Agent: Darby & Darby P.C.

20100087372 - Growth hormone secretion stimulator: Provided are: an agent for promoting growth hormone-secretion, containing a milk-derived basic protein fraction as an active ingredient, with the promotion of growth hormone-secretion being mediated by the promotion of secretion of ghrelin having an effect for promoting growth hormone-secretion; and a method of promoting the secretion of ghrelin by... Agent: Young & Thompson

20100087374 - Methods for treatment and diagnosis of pulmonary diseases based on the expression of serca2 protein: The present invention is directed to methods of treatment of cystic fibrosis. The invention includes a method for treatment of cystic fibrosis in a patient by increasing the activity of sarcoendoplasmic reticulum calcium ATPase (SERCA) in a patient. More specifically, the step of increasing SERCA activity can include but is... Agent: Sheridan Ross PC

20100087370 - Modulation of nitric oxide signaling to normalize tumor vasculature: The instant invention provides methods for treating a solid tumor in a subject comprising modulating nitric oxide production in the tumor to normalize tumor vasculature and administering an anti-tumor therapy to the subject. The invention further provides methods of treating a solid tumor in a subject comprising selectively increasing cyclic... Agent: Edwards Angell Palmer & Dodge LLP

20100087375 - Modulation of synaptogenesis: Soluble proteins, e.g. thrombospondins, can trigger synapse formation. Such proteins are synthesized in vitro and in vivo by astrocytes, which therefore have a role in synaptogenesis. These thrombospondins are only expressed in the normal brain exactly during the period of developmental synaptogenesis, being off in embryonic brain and adult brain... Agent: Morrison & Foerster LLP

20100087365 - Pharmaceutical compositions of hglp-1, exendin-4 and analogs thereof: The present invention is directed to pharmaceutical composition comprising a clear solution or an aqueous mixture, a suspension or a semisolid of at least one peptide compound selected from the group consisting of hGLP-1(7-36)-NH2 and analogs and derivatives thereof, hGLP-1(7-37)-OH and analogs and derivatives thereof and/or exendin-4 and analogs and... Agent: Leon R Yankwich Yankwich & Associates

20100087379 - Polypeptides of botryosphaeria rhodina: The invention relates to functional polypeptides secreted from Botryospaeria rhodina CBS 274.96.... Agent: Novozymes North America, Inc.

20100087367 - Products and methods using soy peptides to lower total and ldl cholesterol levels: Controlled studies demonstrate that products and related methods using soy related peptides lower total and LDL cholesterol levels in individuals. In one exemplary embodiment of the present disclosure, a product containing an effective amount of lunasin peptides that lowers cholesterol levels in an individual that consumes the lunasin peptides is... Agent: Kathryn P.wilke C/o Gaw Van Male

20100087371 - Transglutaminase variants with improved specificity: Variants of transglutaminase from Streptoverticillium ladakanum, which variants have improved selectivity for Gln-141 of human growth hormone are provided.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100087368 - Treating acute renal failure with soluble thrombomodulin variants: The present invention provides a method for preventing and/or treating subjects with acute renal failure caused by a variety of conditions. The method comprises administering to the subject soluble thrombomodulin which does not activate Protein C. In conjunction with standard of care, soluble thrombomodulin that does not activate Protein C... Agent: Eli Lilly & Company

20100087380 - Pharmaceutical compositions for inhibiting intestinal permeability: A method for preventing or delaying the onset of autoimmune diseases is disclosed.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20100087381 - Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues: The present invention relates to a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders or diseases) of the gastrointestinal system. The method comprises administering to a subject in need thereof a therapeutically effective amount of... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100087382 - Inhibitors of hepatitis c ns3 protease: e

20100087383 - Intracerebral oxidation inhibitor and use thereof: The present invention relates to an intracerebral oxidation inhibitor for preventing the onset of mental deterioration, which has early therapeutic effects. Specifically, the present invention relates to: an intracerebral oxidation inhibitor comprising a peptide consisting of Leu and Ile or a modified form thereof as an active ingredient; and a... Agent: Sughrue Mion, PLLC

20100087384 - Jasmonate based assays for identifying compounds that selectively inhibit mitochondrial bound hexokinases: The present invention provides compositions comprising compounds that selectively bind to hexokinases thereby promoting dissociation of these enzymes from mitochondria, and methods of use of such compounds and compositions to induce cell death in diseases and disorders characterized by the high levels of mitochondrial bound hexokinase. The present invention further... Agent: Fennemore Craig

20100087385 - Application of glycyrrhizic acid and its breakdown product glycyrrhetinic acid for the manufacture of a medicament for the treatment of inflammatory bowel disease: The application of glycyrrhizic acid and its breakdown product glycyrrhetinic acid for the treatment of inflammatory bowel disease is disclosed. Glycyrrhizic acid or glycyrrhetinic acid and glycyrrhizinate or glycyrrhetate can treat inflammatory bowel disease by inhibiting inflammatory reactions and antioxidation.... Agent: Sheldon Mak Rose & Anderson PC

20100087386 - Topical use of levofloxacin for reducing lung inflammation: The present invention relates to methods and compositions for the treatment of pulmonary inflammation. In particular, methods and compositions using aerosol levofloxacin or ofloxacin to reduce pulmonary inflammation are provided.... Agent: Knobbe Martens Olson & Bear LLP

20100087508 - Compositions and methods for inhibiting expression of eg5 and vegf genes: This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, and methods of using the compositions to inhibit the expression of the Eg5 and Vascular Endothelial Growth Factor (VEGF), and methods of using the compositions to treat pathological processes mediated by Eg5 and VEGF expression, such... Agent: Alnylam/fenwick

20100087509 - Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts: The present invention relates to methods, agents and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts. The invention thus provides a method, comprising contacting a compound with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID No: 194-309; and measuring... Agent: Martin Savitzky Law Offices Of Martin Savitzky Esq.

20100087507 - Use of rpn2 gene expression inhibitor: The present invention uses an RPN2 gene expression inhibitor as a cancer cell growth inhibitor, which further includes a drug showing an anti-cancer action if desired, and is administered in combination with atelocollagen if desired. In addition, the present invention is an anti-cancer agent including such cancer cell growth inhibitor.... Agent: Greenblum & Bernstein, P.L.C

20100087514 - Method and means for treatment of osteoarthritis: The present invention relates to in vivo and in vitro methods, agents and compound screening assays for inducing anabolic stimulation of chondrocytes, including cartilage formation enhancing pharmaceutical compositions, and the use thereof in treating and/or preventing a disease involving a systemic or local decrease in mean cartilage thickness in a... Agent: Martin Savitzky Law Offices Of Martin Savitzky Esq.

20100087512 - Microrna molecules: In Caenorhabditis elegans, lin-4 and let-7 enclode 22- and 21-nucleotide RNAs, respectively, that function as key regulators of developmental timing. Because the appearance of these short RNAs is regulated during development, they are also referred to as “small temporal RNAs” (stRNAs). We show that many more 21- and 22-nt expressed... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100087513 - Microrna molecules: In Caenorhabditis elegans, lin-4 and let-7 enclode 22- and 21-nucleotide RNAs, respectively, that function as key regulators of developmental timing. Because the appearance of these short RNAs is regulated during development, they are also referred to as “small temporal RNAs” (stRNAs). We show that many more 21- and 22-nt expressed... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100087510 - Novel adaptor protein that binds to mammalian toll-like receptor 3 and gene thereof: A novel adaptor protein and its gene are provided. The novel adaptor protein has a property of binding to mammalian Toll-like receptor 3, which controls type I interferon production that is effective for prevention/treatment of viral infectious disease such as hepatitis B, hepatitis C, and the like, treatment of tumors,... Agent: Nixon & Vanderhye, PC

20100087511 - Spinal muscular atrophy (sma) treatment via targeting of smn2 splice site inhibitory sequences: The present invention is directed to methods and compositions capable of blocking the inhibitory effect of a newly-identified intronic inhibitory sequence element, named ISS-N1 (for “intronic splicing silencer”), located in the SMN2 gene. The compositions and methods of the instant invention include oligonucleotide reagents (e.g., oligoribonucleotides) that effectively target the... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100087387 - Five- and six-membered conformationally locked 2',4'-carbocyclic ribo-thymidines for the treatment of infections and cancer: Compounds (1, 2, 3, 4) according to the formulae shown below: (Formula 1, 2, 3, 4). For General Formula1-4:N=1-Thyminyl,9-Adeninyl,9-Guaninyl,1-Cytosinyl, 5-methyl-1-cytosinyl, 5-trifluoromethyl-1-cytosinyl, 5-fluoro-1-cytosinyl, 5-fluoro-1-cytosinyl, 5-trifluoromethyl-1-Uracilyl or Formula (A) (12a/12b) wherein for 12a: n=1, Q=CH3(R) [5-membered carbocyclic with C7′ in R configuration], 12b: n=1, Q=CH3(S) [5-membered carbocyclic with C7′ in S configuration].... Agent: Frishauf, Holtz, Goodman & Chick, PC

20100087388 - Odcase inhibitors as anti-virals and antibiotics: The present invention includes the utility of anti-viral and/or antibacterial effective amounts of 6-substituted nucleoside derivatives of formula (I) (e.g. 6-iodouridine and 6-iodouridine monophosphate) in the treatment or prevention of viral infections (e.g. Flavivridae, Bunyaviridae, or Togaviridae, or viral infections of hepatitis C, hepatitis B, herpes, influenza, HIV, polio, Coxsackie... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20100087389 - Sensory modifier: Sensory modifiers and compositions comprising sensory modifiers are described. The sensory modifiers comprise polysaccharide carbohydrate having at least about 75% by weight amylopectin and the polysaccharide carbohydrate has been treated and swollen with a substantially anhydrous solvent.... Agent: Unilever Patent Group

20100087391 - Treatment of inflammatory bowel disease: The present invention relates to compositions (including medicaments and nutritional products) for use in the prevention or treatment of Inflammatory Bowel Disease. Such compositions comprise a therapeutically effective amount of a soluble fibre derivable from fruit of the Musa spp. The soluble fibre may in particular be derived from plantains... Agent: Davis Wright Tremaine LLP/los Angeles

20100087390 - Universal sensory structurant: Universal sensory structurants and compositions comprising the same are described. The universal sensory structurants comprise polysaccharide carbohydrate having at least about 75% by weight amylopectin and the polysaccharide carbohydrate has been treated and swollen with a solvent comprising hydroxylated polymer comprising less than about 100 silane repeat units.... Agent: Unilever Patent Group

20100087392 - Complexes of ibuprofen, cyclodextrins and ternary agents and the use thereof in pharmaceutics: The present invention relates to pharmaceutical compositions comprising ibuprofen in the form of an ibuprofen/cyclodextrin/lysine complex having improved pharmacokinetic properties compared with ibuprofen alone, such as a shortened Tmax and an increased Cmax.... Agent: The Firm Of Hueschen And Sage

20100087393 - Methods and compositions of inhibiting complement and cellular activation with dextran sulfate: A method of inhibiting the adverse effects of complement pathway, activation products in a subject comprising administering to the subject an amount of Dextran Sulfate effective to inhibit formation of alternative complement pathway activation product.... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20100087394 - Compositions containing betaine and hydrophobic silica: m

20100087395 - Cosmetic preparation:

20100087396 - Novel compounds having selective inhibiting effect at gsk3: wherein Z is N; Y is CONR5, NR5CO, SO2NR5, NR5SO2, CH2NR5, NR5, NR5CONR5, CH2CO, CO, O or CH2O; X is CH or N; P is phenyl or a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms selected from N, O or S and said phenyl ring or... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100087397 - Use of lipid conjugates in the treatment of conjunctivitis: In one embodiment, the invention provides a method of suppressing, inhibiting, preventing, or treating conjunctivitis in a subject, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound via an ester or amide bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a... Agent: Pearl Cohen Zedek Latzer, LLP

20100087398 - Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions: The use of dihydropyridine-5-phosphonic acid cyclic propylene ester derivatives of formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug in the treatment of cancers, pre-cancerous conditions and other conditions is disclosed, wherein each of R1-R8 are the same or different, are hydrogen or C1-C6... Agent: Scully, Scott, Murphy & Presser, P.C.

20100087399 - Use of 9-oxoacridine-10-acetic acid, salts and esters thereof in combination therapy of ovarian cancer: The present invention provides novel methods of combination therapy of ovarian cancer, pharmaceutical kits and combinations of 9-oxoacridine-10-acetic acid and/or salts and/or esters thereof with one or more chemotherapeutic agents. The proposed combination therapy is useful in enhancing the action of chemotherapeutic agents and their proliferative activity on human ovarian... Agent: Patentica LLC

20100087400 - Beta-hydroxy-gamma-aminophosphonates and methods for the preparation and use thereof: The present invention provides β-hydroxy-γ-aminophosphonates, β-amino-γ-aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these β-hydroxy-γ-aminophosphonates, β-amino-γ-aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100087401 - Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives: A method of increasing the bioavailability of balsalazide by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of balsalazide in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication... Agent: Edwards Angell Palmer & Dodge LLP

20100087402 - Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders: The present invention relates to the treatment of estrogen-dependent hyperproliferative uterine disorders including endometriosis, uterine fibroids, endometrial hyperplasia, uterine cancer, and their related symptoms by intravaginally administering at least two active agents selected from an aromatase inhibitor, an antiinflammatory agent, and a uterine-selective estrogen receptor antagonist. This combination therapy reduces... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100087403 - Topical treatment of skin infection: The invention relates to an unexpected discovery that propylene glycol is highly effective at killing or inhibiting Propionibacterium acnes in a mammalian skin disorder, as well as to the use of propylene glycol and salicylic acid in a skin-disorder treatment. This invention also relates to compositions containing propylene glycol alone... Agent: Merchant & Gould PC

20100087405 - Food supplementation composition containing one or more vitamin d3 compounds and one or more magnesium salts: Use of one or more vitamin D3 compounds chosen from the group 1-α-hydroxy vitamin D3, 25-hydroxy vitamin D3, 1-α-,25-dihydroxy vitamin D3, in combination with one or more magnesium salts to prevent milk fever in animals.... Agent: Nixon & Vanderhye, PC

20100087404 - Method of treating and preventing hyperparathyroidism with active vitamin d analogs: This invention relates to a method for treating or preventing hyperthyroidism secondary to chronic kidney disease by administering a sufficient amount of an active vitamin D analog utilizing a variety of effective treatment protocols.... Agent: Michael Best & Friedrich LLP

20100087406 - Induction of innate immunity by vitamin d3 and its analogs: Cationic antimicrobial peptides (AMPs) are an integral part of the innate immune system. Cathelicidin and defensin homologs from a variety of species exhibit broad-range bactericidal activity. The human cathelicidin analog, hCAP18, is encoded by the CAMP gene. Vitamin D3 and its analogs upregulate transcription of CAMP and defensin β2 (defB2)... Agent: Davis Wright Tremaine LLP/los Angeles

20100087407 - use of aromatase inhibitors: The invention provides a method of thinning the endometrium in a woman by utilizing a therapeutically effective amount of an aromatase inhibitor.... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz And Cohn

20100087410 - Aryl aniline derivatives as beta2 adrenergic receptor agonists: The invention provides novel β2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.... Agent: Theravance, Inc.

20100087409 - Composition comprising an antibiotic and a corticosteroid: This invention relates to compositions (e.g., otic compositions) comprising an antibiotic (generally a quinolone or naphthyridinone), corticosteroid, and organic acid (generally a fatty acid). This invention also relates to treatment methods using such a composition, uses of such a composition to make medicaments, and therapeutic kits comprising such a composition.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20100087408 - Non-hormonal steroid modulators of nf-kb for treatment of disease: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy.... Agent: Global Patent Group - Vld

20100087412 - Micronized eplerenone compositions: The invention relates to oral pharmaceutical compositions useful as aldosterone receptor blockers comprising the active agent micronized eplerenone in an amount of about 10 mg to about 1000 mg and one or more carrier materials.... Agent: Pfizer Inc. Patent Department

20100087411 - Substituted sapogenins and their use: The invention discloses substituted sapogenins and their use in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed... Agent: Hoffmann & Baron, LLP

20100087413 - Prevention and treatment of inflammation-induced and/or immune-mediated bone loss: The present invention relates to the use of an 11-β-HSD-type 1 and or type 2 inhibitor for the manufacture of a pharmaceutical agent for the prevention and/or treatment of inflammation-induced and/or immune-mediated loss of bone and/or cartilage.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100087414 - Method and intermediates for the preparation of derivatives of n (1-benzhydrylazetidin-3-yl)-n-phenylmethylsulfonamide: The invention relates to a novel method for the synthesis of N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5 -difluorophenyl)methylsulfonamide.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100087415 - Inhibitors of store operated calcium release: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases, disorders or conditions that would benefit from inhibition of SOC... Agent: Wilson, Sonsini, Goodrich & Rosati

20100087416 - Aerosol fluoroquinolone formulations for improved pharmacokinetics: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.... Agent: Knobbe Martens Olson & Bear LLP

20100087417 - Amino-pyridine derivatives as s1p1 /edg1 receptor agonists: The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.... Agent: Hoxie & Associates LLC

20100087418 - Benzoxazepine derivatives and use thereof: wherein each symbol is as defined in the description [with the proviso that 9-chloro-7-(1,1-dimethylethyl)-2,3,4,5-tetrahydro-1,4-benz-oxazepine and N-[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1,4-benz-oxazepin-7-yl)-5-oxazolidinyl]methyl]acetamide are excluded], salts of the same, and prodrugs thereof have selective activation effect on serotonin 5-HT2C receptor and are useful as preventive and therapeutic agents for lower urinary tract diseases, obesity, and/or pelvic organ... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100087420 - Heterotricyclic metalloprotease inhibitors: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and... Agent: Amgen Inc.

20100087419 - Hiv integrase inhibitors: wherein X1, X2, Y, R1A, R1B, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset or progression of AIDS. The compounds are employed against HIV infection and AIDS as compounds per... Agent: Merck And Co., Inc

20100087421 - Method to determine the risk for side effects of an ssri treatment in a person: A new method is found to determine an increased risk for side effects of an SSRI treatment in a person by genotyping the person for the presence of the 102 C/C DNA sequence in the 5-HT2A receptor gene. This provides for a method to improve the treatment of an SSRI... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20100087422 - Treatment of adhd: A method is described for treating attention deficit hyperactivity disorder (ADHD), by administering to the individual an anti-epileptic mood stabiliser at a dose which is sub-therapeutic for mood stabilisation, optionally in combination with a psychostimulant. Also described is a method of improving reading comprehension and/or fluency in an individual suffering... Agent: Stites & Harbison, PLLC

20100087423 - New benzamide derivatives as bradykinin antagonists: R1-R5 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective antagonists of bradykinin B1, to processes for producing these compounds, to pharmacological compositions containing them and to their use in therapy or prevention of painful and... Agent: Fish & Richardson P.C.

20100087424 - Tricyclic nitrogen containing heterocycles as antibacterial agents: Tricyclic nitrogen containing compounds and their use as antibacterials.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100087425 - Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors: i

20100087426 - Process and intermediates for the synthesis of 8-[-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds: This application discloses a novel process to synthesize 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds, which may be used, for example, as NK-1 inhibitor compounds in pharmaceutical preparations.... Agent: Monte Browder, Esq

20100087428 - Novel potassium channel blockers: i

20100087427 - Pyrrolidine derivatives for the treatment of a disease depending on the activity of renin:

20100087429 - Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use: wherein A1, A2, A3, A4, A5, A6, T1, T2, W, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include,... Agent: Amgen Inc.

20100087430 - Novel benzofuran potassium channel blockers and uses thereof: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis,... Agent: Scully Scott Murphy & Presser, PC

20100087431 - Triazolyl aminopyrimidine compounds: The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.... Agent: Eli Lilly & Company

20100087433 - Methods of inhibiting tryptophan hydroxylase: Compounds, compositions and methods of treating serotonin-mediated diseases and disorders are disclosed.... Agent: Lexicon Pharmaceuticals, Inc.

20100087435 - Modulators of atp-binding cassette transporters: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Vertex Pharmaceuticals Inc.

20100087434 - Nk-1 and serotonin transporter inhibitors: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100087432 - Pyrrole derivatives having crth2 receptor antagonist activity: There are provided according to the invention compounds of formula (I) as CRTh2 antagonists. In free or salt form, wherein R3, R4, R5, R6, Q, W and n are as described in the specification, process for preparing them, and their use as pharmaceuticals.... Agent: Novartis Corporate Intellectual Property

20100087436 - Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection: Methods of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20100087437 - Novel potassium channel blockers: t

20100087438 - New potassium channel blockers:

20100087439 - Novel preventive and/or therapeutic agent for neuropathic pain: The present invention relates to an agent for preventing and/or treating neuropathic pain comprising a 2-[(substituted-inden-7-yloxy)methyl]morpholine of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. The invention is useful for providing an excellent agent for preventing and/or treating neuropathic pain, and particularly useful for providing... Agent: Fitzpatrick Cella Harper & Scinto

20100087440 - Phosphatidylinositol 3-kinase inhibitors and methods of their use: The present invention comprises small molecule inhibitors of phosphatidylinositol 3-kinase (PI3K), which is associated with a number of malignancies such as ovarian cancer, cervical cancer, breast cancer, colon cancer, rectal cancer, and glioblastomas, among others. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting these... Agent: Patent Dept Exelixis, Inc.

20100087441 - Prognostic method: A method for prognosing a rheumatoid arthritis phenotype using the outcomes of selected single nucleotide polymorphisms (SNPs) and clinical variables. A method for genotyping multiple rheumatoid arthritis associated genetic variations comprising use of a DNA microrarray. A microarray for use in the described methods.... Agent: Wolf Greenfield & Sacks, P.C.

20100087442 - Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient: The compound of formula (I) has an inhibitory activity against cysteine protease, and it is useful for the treatment of inflammatory diseases, immune diseases, ischemic diseases, respiratory diseases, circulatory diseases, blood diseases, neuronal diseases, hepatic or biliary diseases, osseous or articular diseases, metabolic diseases, etc. And the compound has inhibitory... Agent: Sughrue Mion, PLLC

20100087443 - 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators: e

20100087444 - Imatinib mesylate: There is provided a solid dispersion of imatinib mesylate that includes imatinib mesylate and a pharmaceutically acceptable carrier, wherein said carrier is a cellulose derivative. Also provided is a process for making a solid dispersion and a process for making imatinib.... Agent: Dr. Reddy''s Laboratories, Inc.

20100087445 - Aryl piperazine derivatives useful for the treatment of neuropsychiatry disorders: This invention provides novel aryl piperazine derivatives represented by Formula (I) having medical utility, in particular as modulators of dopamine and serotonin receptors, preferably the D3, 5HT1A and 5-HT2A receptor subtypes, and in particular useful for the treatment of neuropsychiatric disorders, incl. schizophrenia.... Agent: Birch Stewart Kolasch & Birch

20100087446 - 2-substituted indole derivatives as calcium channel blockers: 2-Substituted indole derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium... Agent: Merck And Co., Inc

20100087447 - Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination: [wherein R1 and R2 independently represent a hydrogen atom or a halogen atom; and R3 represents a hydrogen atom or an amino-protecting group] or a salt thereof and at least one neuraminidase inhibitor. The pharmaceutical composition is useful for a treatment including the treatment or prevention of influenza. Also disclosed... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100087448 - Dihydropyrimidine compounds and their uses in preparation of medicaments for treating and preventing antiviral diseases: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof, to a process for preparing the compound of formula (I), and to use of the compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof as a medicament, in particular... Agent: Brinks Hofer Gilson & Lione

20100087449 - Heteroarylamide pyrimidone compounds: e

20100087450 - Organic compounds: The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment and/or prophylaxis of narcolepsy.... Agent: Hoxie & Associates LLC

20100087451 - Polymorph b of n--n-methyl-acetamide: The present invention relates to a novel polymorph of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methyl-acetamide, processes for its preparation, its use as a medicament, its use in the manufacture of a medicament, and pharmaceutical compositions comprising the novel polymorph.... Agent: Birch Stewart Kolasch & Birch

20100087452 - Pyridyl-triazolopyrimidine derivative or its salt, pesticide containing it and its production process: To provide a novel pesticide. The present invention provides a pesticide containing a pyridyl-triazolopyrimidine derivative represented by the formula (I) or its salt as an active ingredient: wherein R1 is substitutable alkyl, substitutable cycloalkyl, substitutable alkenyl, substitutable alkynyl, halogen, cyano, aryl, a heterocyclic group which may be substituted by alkyl,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100087453 - Compounds, screens, and methods of treatment: The present invention features compounds of Formula (I), pharmaceutical compositions, methods of synthesis, and methods for treating diseases and conditions associated with cellular necrosis. Screening assays for identifying compounds useful for treating these conditions are also described.... Agent: Clark & Elbing LLP

20100087454 - Mucosal bioadhesive slow release carrier for delivering active principles: A mucosal bioadhesive slow release carrier comprising an active principle, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains at least one bioadhesive natural protein of vegetal origin and preferably a pea protein from the genus Pisum or the species Pisum... Agent: Birch Stewart Kolasch & Birch

20100087455 - Substituted xanthine compounds: The present invention relates to new substituted xanthine-based agents, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100087456 - Pyridopyrimidinone inhibitors of pi3k-alpha and mtor: e

20100087459 - Forms of lapatinib compounds and processes for the preparation thereof: The present invention provides novel crystalline and amorphous lapatinib compounds and processes for preparing them... Agent: Kenyon & Kenyon LLP

20100087457 - Dosages and methods for the treatment of cancer: In general, the invention relates to a pharmaceutical dose having (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride as the active ingredient that upon administration to a subject provides a Cmax of about 1 ng/mL to about 250 ng/mL. The dose may be used in methods of treating cancer through the administration of (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride. The... Agent: Myriad Pharmaceuticals, Inc. C/o Cpa Global

20100087458 - Method of treating melanoma: Disclosed is (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride effective as a cytotoxic agent. (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride is useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to its use in treating melanoma.... Agent: Myriad Pharmaceuticals, Inc. C/o Cpa Global

20100087461 - Arylamide pyrimidone compounds: s

20100087460 - Arylamide pyrimidone derivatives:

20100087467 - Compositions useful as inhibitors of protein kinases: or a pharmaceutically acceptable derivative thereof, wherein A, B, Q, R1, and R2 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of AKT or PDK1 kinase, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides pharmaceutical compositions comprising the... Agent: Vertex Pharmaceuticals Inc.

20100087465 - Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders: Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active.... Agent: Metabolex, Inc. C/o Swiss Tanner, P.C.

20100087462 - Methods for predicting and detecting intolerance to an hypolipidemic agent: The invention describes methods and tools for the identification of drug intolerance into subjects receiving an hypolipidemic agent. The invention further describes methods and tools for the prediction of drug intolerance in subjects in need of hypolipidemic agents. Some aspects of the invention are based on the assessment of the... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20100087466 - Novel small molecule dnak inhibitors: Methods of inhibiting HSP70 proteins, agents causing the inhibition of HSP70 proteins, and the effects of such inhibition on cell proliferation. Anti-microbial agents comprising small molecules, or pharmaceutical salts thereof, disclosed herein and further methods of use thereof are also disclosed. The disclosed small molecules, or pharmaceutical salts thereof, are... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20100087463 - Pharmaceutical compositions comprising nilotinib or its salt: A pharmaceutical composition, especially capsules. comprising granules containing nilotinib or a salt thereof with at least one pharmaceutically acceptable excipient. The granules may be produced by a wet granulation process.... Agent: Novartis Corporate Intellectual Property

20100087464 - Protein kinase inhibitors and methods for using thereof: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or... Agent: Genomics Institute Of The Novartis Research Foundation

20100087468 - Modulators of ppar and methods of their preparation: The present invention is directed to certain novel compounds represented by Formula (I) and pharmaceutically acceptable salts, solvates, hydrates and prodrugs thereof. The present invention is also directed to methods of making and using such compounds and pharmaceutical compositions containing such compounds to treat or control a number of diseases... Agent: Townsend And Townsend And Crew, LLP

20100087470 - Buprenorphine-wafer for drug substitution therapy: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100087469 - Natural product derivatives with antimalarial activity: The present invention provides new chemical compositions with desirable biological activity and toxicity profiles for the enhanced treatment of malaria.... Agent: Shuren Zhu

20100087471 - Indole and indoline derivatives and methods of use thereof: e

20100087472 - Use of methylnaltrexone and related compound to treat constipation in chronic opioid users: A method of preventing or treating constipation in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with... Agent: Wolf Greenfield & Sacks, P.C.

20100087473 - Freeze-dried injectable pharmaceutical combination of semisynthetic vinca alkaloids and carbohydrate stable at room temperature: This invention relates to pharmaceutical compositions consisting of a semisynthetic derivative of vinca alkaloid, stable at room temperature, in which said derivative is present in the form of a freeze dried product obtained in the presence of at least one carbohydrate.... Agent: Birch Stewart Kolasch & Birch

20100087474 - Materials and methods for enhanced degradation of mutant proteins associated with human disease: The invention features compositions and methods that are useful for treating or preventing a protein conformation disease in a subject by enhancing the degradation of misfolded proteins in vivo.... Agent: Edwards Angell Palmer & Dodge LLP

20100087475 - Pharmaceutical compounds: This application describes substituted 1,3,4,6,7,11b-hexahydro-benzo(a)quinolizine compounds, pharmaceutical compositions containing them, processes for making them and their therapeutic methods.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100087476 - Pharmaceutical compounds: This application describes methods of treatment and/or prophylaxis of asthma that involve administration of dihydrotetrabenazine, and isomers and/or pharmaceutically acceptable salts thereof.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100087478 - Hif-1 inhibitors: HIF-1 inhibitors and methods of their use are provided. In particular, 2,2-dimethylbenzopyran based compounds and methods of their use, for example in the treatment or prevention of hypoxia-related pathologies are provided.... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20100087477 - Selective glycosidase inhibitors: The present invention provides glucoimidazole derivatives and methods of making them. The compounds can be used to inhibit the activity of O-GlcNAcase enzymes, including both bacterial OGA (bOGA) and human OGA (hOGA) and can be selective, showing low inhibition of hexosaminidases. The compounds can be used to study the role... Agent: Myers Bigel Sibley & Sajovec

20100087479 - Compositions useful as inhibitors of voltage-gated sodium channels: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20100087480 - Substituted phenylmethyl bicyclocarboxyamide compounds: This invention provides a compound of the formula (I). These compounds are useful for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound.... Agent: Pfizer Inc. Patent Department

20100087481 - Oral pharmaceutical formulations for antidiabetic compounds: Oral pharmaceutical preparations of salts and polymorphs of a compound useful in the treatment of inflammatory and metabolic conditions and diseases are provided herein. The oral pharmaceutical preparation is useful for the treatment or prevention of conditions and disorders associated with energy homeostasis such as type II diabetes, lipid metabolism,... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100087482 - Method for treating gefitinib resistant cancer: The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer... Agent: David S. Resnick

20100087483 - Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht 4-antagonists: The present invention is concerned with novel compounds of formula (I) having 5HT4-antagonistic properties. The invention further relates to methods for preparing such novel compounds, pharmaceutical compositions comprising said novel compounds as well as the use as a medicine of said compounds.... Agent: Woodcock Washburn LLP

20100087485 - 4-aminopiperidine derivatives: wherein R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, non-insulin dependent diabetes mellitus and/or impaired glucose tolerance, obesity, and/or metabolic syndrome or β-cell... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100087484 - Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands: The present invention relates to novel aminoalkoxy arylsulfonamide compounds of the formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, their derivatives, their stereoisomers, their pharmaceutically acceptable... Agent: Iphorgan, Ltd.

20100087486 - Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions: A pharmaceutical composition useful in the prevention of subconjunctival scarring that may occur after glaucoma filtration surgery comprising an effective amount of an activin receptor-like kinase 5 inhibitor. Also disclosed is a method of treating corneal haze and subconjunctival scarring that may develop after ocular surgery comprising applying an amount... Agent: Benesch, Friedlander, Coplan & Aronoff LLP Attn:IPDepartment Docket Clerk

20100087487 - 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) including any stereochemically isomeric form thereof, or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein all radicals are defined in the application and claims. The compounds according to the invention are positive... Agent: Gardner Groff Greenwald & Villanueva. PC

20100087490 - Dosage units of 3-(6-(1-(2,2-difluorobenzo[d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid: The present invention relates to formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid in Form I, pharmaceutical packs or kits thereof, and methods of treatment therewith.... Agent: Vertex Pharmaceuticals Inc.

20100087489 - Phenyl and benzodioxinyl substituted indazoles derivatives: e

20100087488 - Physiologically acceptable salts of 3-[(2--1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester: The invention relates to new salt forms of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100087491 - Polycyclic compounds: e

20100087492 - Systemic treatment of blood-sucking and blood-consuming parasites by oral administration of a parasiticidal agent: Pharmaceutically acceptable single parasiticidal agent compositions of imidacloprid for oral delivery to mammals to systemically control targeted blood-sucking or blood-consuming parasites, such as fleas, ticks and certain species of helminthes and scabies.... Agent: Dla Piper LLP (us)

20100087493 - Method for improving the pharmacokinetics of drugs metabolized by ugt2b10: A method for modifying the pharmacokinetics of a pharmacologically active agent that undergoes direct N-glucuronidation by UDP-glucuronosyltransferase isoenzyme UGT2B10 in a human subject comprising administering an effective amount of an UGT2B10 modulator to said human subject. A method for identifying compounds which are directly metabolized by UGT2B10 or which act... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100087494 - Fungicide n-(3-phenylpropyl) carboxamide derivatives: m

20100087495 - Phenyl derivatives and their use as immunomodulators: The invention relates to phenyl derivatives of formula (I), their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.... Agent: Hoxie & Associates LLC

20100087496 - Novel cinnamic amide derivatives useful as ion channel modulators: This invention relates to novel cinnamic amide derivatives that are found to be potent modulators of ion channels and, as such, they are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to modulation of ion channels.... Agent: Birch Stewart Kolasch & Birch

20100087497 - Benzimidazole anthelmintic compositions: The present invention provides a veterinary anthelmintic composition that includes: at least 10% w/v of a benzimidazole anthlemintic; and b) a water-immiscible solvent system, which comprises a lactone solvent, an essential oil, and surfactant.... Agent: Wyeth LLC Patent Law Group

20100087498 - Use of biotin to prevent photoaging: Use of biotin, preferably in a combination of biotin and (-)-epigallocatechin gallate (EGCG) in a specific ratio, to prevent sunlight-induced aging (photoaging) of the skin.... Agent: Nixon & Vanderhye, PC

20100087499 - Pharmaceutical compositions and methods of using temozolomide and multi-targeted kinase inhibitors: The present invention provides formulations, kits and methods useful for treating cell proliferative disorder. In particular, the formulations, kits and methods include temozolomide (TMZ) in combination with a multi-targeted kinase inhibitor.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20100087501 - Highly bioavailable composition containing eprosartan-poloxamer complex or 2-(7-chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3h-pyridazine (4,5-b)indol-1-yl)-n,n-dimethylacetamide - poloxamer complex: A composition including an association complex of a pharmaceutical composition and one or more polyethylene-polypropylene glycol block copolymers (poloxamers) is provided. The pharmaceutical composition may include a member selected from the group consisting of (a) an association complex of an eprosartan composition including eprosartan or a pharmaceutically acceptable salt of... Agent: Howson & Howson LLP

20100087500 - Methods and compositions for treatment of acute heart failure: The present disclosure provides methods and compositions for treating acute heart failure, by administering to a subject in need thereof a therapeutically effective amount of an AICA riboside analog or a pharmaceutically acceptable salt or prodrug thereof.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20100087502 - Indazoles used to treat estrogen receptor beta mediated disorders: The present invention relates to novel indazole derivatives having pharmacological activity, processes for their preparation, compositions containing them and uses of these compounds in the treatment of estrogen receptor beta mediated diseases.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100087503 - Ketorolac tromethamine compositions for treating or preventing ocular pain: The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution which provides increased visual acuity in users and wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a... Agent: Allergan, Inc.

20100087504 - Use of diindolylmethane (dim) compounds and derivatives as neuroprotective agents: Presented herein are diindolylmethane derivative compounds useful for the prevention and or treatment of neurological conditions, including neurological conditions related to neuroinflammation. One such neurological condition is Parkinson's disease.... Agent: Swanson & Bratschun, L.L.C.

20100087505 - Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors: e

20100087506 - Cyclic amine compound: wherein R1 is a hydrogen atom, a halogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom or a group via a sulfur atom; R2 is a hydrogen atom, a halogen atom, a group via a carbon atom, a group... Agent: Edwards Angell Palmer & Dodge LLP

20100087515 - Ikk-beta serine-threonine protein kinase inhibitors: Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms;... Agent: Banner & Witcoff, Ltd.

20100087516 - Antibacterial macrolactin a that bacillus polyfermenticus kjs-2 produced in: The present invention relates to uses of Macrolactin A produced by Bacillus polyfermenticus KJS-2 (KCCM 10769P), which is a new bacillus strain, as an antibiotic. Macrolactin A of the present invention, which is produced by Bacillus polyfermenticus KJS-2, shows a broad spectrum of antibiotic activity against a variety of microorganisms... Agent: Birch Stewart Kolasch & Birch

20100087517 - Prodrugs of substituted 1,3-dioxanes and their uses: The present invention relates to prodrugs of compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The prodrugs of the compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used... Agent: Fenwick & West LLP

20100087518 - Delta 9 - tetrahydrocannabinol processing: The present invention provides a process for handling Δ9-THC, which comprises preparing a solution of Δ9-THC in a solvent which exists as a gas at room temperature and atmospheric pressure. The invention also provides solutions of Δ9-THC in the solvent and solid preparations of Δ9-THC.... Agent: Knobbe Martens Olson & Bear LLP

20100087519 - Use of equol for treating androgen mediated diseases: Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These... Agent: Brinks Hofer Gilson & Lione

20100087520 - Stable solutions of orlistat for pharmaceutical dosage forms: Liquid orlistat-containing fill materials suitable for encapsulating in hard or soft capsules are described herein. The fill material contains orlistat dissolved in one or more medium chain triglycerides or medium chain partial triglycerides, one or more citrate esters, and combinations thereof. The fill material can also contain one or more... Agent: Pabst Patent Group LLP

20100087521 - Biologically active complex: where X is an optionally substituted divalent saturated hydrocarbon group containing 2-8 carbon atoms in the chain connecting the two OH groups; and its use for stimulating cells to produce cytokines and for treating mammalian diseases and conditions responsive to increased production of cytokines The complex may be used also... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100087522 - Novel muscle relaxant using negative charge gold nanoparticle with choline: A drug having a muscle relaxing effect can be prepared by binding negatively charged gold nanoparticles having a size of 1.4 nm fitted to synaptic clefts to choline through ionic bonds, thereby inducing gold-sulfur bonds in the Cys loop of an acetylcholine receptor in neuromuscular junction, and thus blocking the... Agent: Seed Intellectual Property Law Group PLLC

20100087523 - Rupestonic acid derivatives and use thereof: Rupestonic acid derivatives are rupestonic acid derivative A- or B-type compounds, prepared through a condensation reaction from starting materials, i.e., a monomer compound of rupestonic acid and an aromatic amine or fatty amine or an organic alcohol, i.e., a fatty alcohol or an aromatic alcohol. Rupestonic acid, which is the... Agent: Robert E. Bushnell & Law Firm

20100087524 - Flavour improving substances: One aspect of the invention relates to a product selected from the group consisting of foodstuffs, beverages, oral care products, tobacco products and flavourings, said product containing at least 0.01 mg/kg of one or more flavour improving substances selected from the group of substituted phenol esters represented by the following... Agent: Curatolo Sidoti Co., Lpa

20100087525 - Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester: The present invention relates to a stereoselective enzymatic synthesis of (S) or (R)-iso-butyl-glutaric ester, an intermediate of S-Pregabalin.... Agent: Kenyon & Kenyon LLP

20100087526 - Inhibitors of polyisoprenylated methylated protein methyl esterase: Inhibitors of the enzyme prenylated methylated protein methyl esterase (PMPMEase), the last step in the prenylation process for many eukaryotic proteins, having the general structure R1—X-A-B(R2)—Y or R1—X-A(R2)—B—Y, where R1 is preferably a polyisoprenyl group, X is a linking group, Y is a group that promotes affinity interactions to the... Agent: ParksIPLaw LLC

20100087527 - Curcumin derivatives: h

20100087528 - Enzymatic peracid production using a cosolvent: Disclosed herein are two-component enzymatic peracid generation systems and methods of using such systems wherein the first component comprises a formulation of at least one enzyme catalyst having perhydrolysis activity, a carboxylic acid ester substrate, and a cosolvent and wherein the second component comprises a source of peroxygen in water.... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20100087530 - Methods for washing poultry during processing with medium chain peroxycarboxylic acid compositions: The present invention relates to methods for reducing microbial contamination on poultry, or on surfaces used in processing poultry, employing compositions including medium chain peroxycarboxylic acid, and to the compositions. The methods include applying a medium chain peroxycarboxylic acid composition to poultry or to the surfaces.... Agent: Ecolab Inc.

20100087529 - Perhydrolases for enzymatic peracid generation: Disclosed herein are variants enzymes that are structurally classified as CE-7 enzymes and have perhydrolysis activity. Also disclosed herein is a process for producing peroxycarboxylic acids from carboxylic acid esters using the aforementioned variant enzymes as well as methods and compositions comprising the variant enzymes. Further, disinfectant formulations comprising the... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20100087531 - Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain: The present invention relates to compositions comprising the triterpenes, dihydrobutyrospermol, dihydrolupeol and/or dihydroparkeol, the composition being applicable as a pharmaceutical, a dietary supplement or as a cosmetic. Further, the invention relates to the use of such compositions for the preparation of a medicament, a dietary supplement or a cosmetic for... Agent: Birch Stewart Kolasch & Birch

20100087532 - Modulation of signal transduction: A polypeptide is identified as being functionally included in a signal transduction pathway having a biological effect. Contemplated polypeptides are different from a retinoic acid receptor, a retinoid X receptor, or a cellular retinoic acid binding protein, however bind a retinoid or retinoid metabolite, and binding of the retinoid or... Agent: Fitch Even Tabin & Flannery

20100087533 - Composition: A phytochemical composition for use as a veterinary dietary supplement comprising alpha linolenic acid (ALA) and up to 10% gamma linolenic acid (GLA). Preferably the ALA source is flax seed oil and GLA is sourced from borage oil.... Agent: O'brien Jones, PLLC

20100087534 - Use of a photosensitizing agent in the treatment or prevention of an inflammation-associated disorder in the gastrointestinal tract of a mammal: The present invention relates generally to the field of Photodynamic therapy (PDT) and more particularly to the use of a photosensitizing agent for the preparation of a medicament for the treatment or prevention of an inflammation-associated disorder in the gastrointestinal tract of a mammal, wherein the expression of pro-inflammatory markers... Agent: Harness, Dickey & Pierce, P.L.C

20100087535 - External composition for skin: A moisturizing agent comprising one or more than one compound selected from the group consisting of lysyl-β-alanine represented by the following general formula (1) and a salt thereof:... Agent: Foley And Lardner LLP Suite 500

20100087536 - Amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof: The present invention provides a prodrug of propofol and crystalline forms thereof, methods of making the propofol prodrug and crystalline forms thereof, pharmaceutical compositions of the propofol prodrug and crystalline forms thereof, methods of using the propofol prodrug and crystalline forms thereof and pharmaceutical compositions thereof to treat diseases or... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20100087537 - Reduced irritant enema for the treatment of inflammatory bowel disease (ibd): The present invention comprises packaged enemas for the treatment of Inflammatory Bowel Disease (IBD), having substantially pure 5-ASA as the active ingredient, with a liquid carrier medium having a material avoidance of bowel irritant substances, such as anti-oxidants for the 5-ASA active ingredient, including such sulfites as potassium metabisulfite, for... Agent: Thompson Hine L.L.P. Intellectual Property Group

20100087538 - Drug substance preparations, pharmaceutical compositions and dosage forms: The invention relates to drug substance preparations, pharmaceutical compositions and dosage forms containing (R)-(−)-2-(2-fluoro-4-biphenylyl) propionic acid as the active pharmaceutical ingredient, and limited amounts of specific product-related and process-related impurities.... Agent: Myriad Pharmaceuticals, Inc. C/o Cpa Global

20100087539 - N'--3-amino-3-phenylpropeonic acid and the pharmaceutically acceptable derivatives thereof, a method for the production and the use thereof in the form of a medicinal agent: The invention relates to the field of organic chemistry and medicine, in particular to virology. More specifically the invention relates to a novel chemical compound N′-{N-[3-oxo-lupan-28-oyl]-9-aminononanoyl}-3-amino-3-phenylpropionic acid of formula 1 and to pharmaceutically acceptable salts and prodrug forms thereof exhibiting an anti-viral (anti-HIV) and immunostimulating activity. A method for producing... Agent: Ladas & Parry LLP

20100087540 - Pharmaceutical composition: Provided is a pharmaceutical composition comprising: a) a prostaglandin compound; (b) a sugar alcohol; (c) a polyol; and (d) a pharmaceutically acceptable carrier. The composition of the present invention can be stored stably even in a polyethylene container. In addition, the composition of the present invention can be stored stably... Agent: Sughrue Mion, PLLC

20100087541 - Compounds for the treatment of metabolic disorders: o

20100087542 - Improvement of the biological action of agrochemical compositions when applied to the cultivation substrate, suitable formulations and use thereof: In soil application, the action of crop protection compositions comprising active compounds from the class of the insecticidal phthalic acid diamides can be improved by adjuvants. The present invention describes corresponding methods and suitable compositions.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100087543 - Pharmaceutical use of substituted amides: The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydro-genase type 1 (11βHSD1) and the use of these compounds as pharmaceutical composi-tions, are described. Also a novel class of substituted amides, their use in therapy, phar-maceutical compositions comprising the compounds, as well as their use in the manufac-ture... Agent: High Point Pharmaceuticals, Inc.

20100087544 - N, n -dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same: The present invention relates to N,N-dimethyl imidodicarbonimidic diamide acetate, a method of preparing the same and a pharmaceutical composition comprising the same, and more particularly, to N,N-dimethyl imidodicarbonimidic diamide acetate which is a crystalline acid addition salt prepared by reacting N,N-dimethyl imidodicarbonimidic diamide with acetic acid, and which is very... Agent: Heslin Rothenberg Farley & Mesiti PC

20100087545 - Purification process: e

20100087546 - Use of dimethyl sulfone (msm) to reduce homocysteine levels: A method for reducing elevated levels of homocysteine in a subject comprising the steps of measuring the level of homocysteine in a subject; detecting an elevated level of homocysteine in the subject; and responsive to said step of detecting, administering to said subject a nutritional supplement comprising dimethyl sulfone (MSM).... Agent: Knobbe Martens Olson & Bear LLP

20100087547 - Use of a blood-flow decrease preventing agent in conjunction with insufflating gas: A blood-flow decrease preventing agent is used to negate or reduce the decreased oxygen delivery in abdominal organs caused by insufflating gas. Preferably a gas is delivered into the abdominal cavity consisting essentially of the insufflating gas and the blood-flow decrease preventing agent. Very preferably, a gas is used consisting... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100087548 - Dual phase cosmetic composition: The present invention relates to a method of formulating a liquid dual phase cosmetic or pharmaceutical composition in which the phases are separate before and after being mixed, the method comprising combining an aqueous phase and an oil phase, wherein one of the aqueous and oil phases has incorporated therein,... Agent: Karen A. Lowney, Esq. Estee Lauder Companies

20100087549 - Extended release excipient and its use: A controlled release excipient composition suitable in formulation of a slow or extended release tablet, contains a synergistic mixture of substantially uncross-linked carboxymethyl starch, or sodium starch glycolate (SSG), and a hydrophilic, non-ionic cellulose ether, preferably hydroxypropylmethylcellulose. Whether or not a SSG in the mixture is sufficiently uncross-linked in the... Agent: Young & Thompson

20100087550 - Formulations with a tertiary amine oxide: c

20100087551 - Cosmetic material: A cosmetic material includes a component selected from diethyl amino hydroxy benzoyl hexyl benzoate and/or 4-tert-buthyl-4′-methoxy dibenzoyl methane as a component that crystallizes and precipitates easily and blends, as a dissolution stabilizer of the component, one or more types of octyl hydroxy stearate oligomer selected from a dimer to heptamer... Agent: Knobbe Martens Olson & Bear LLP

  
04/01/2010 > patent applications in patent subcategories. category listing, related patent applications

20100081609 - Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin: Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions.... Agent: Theravance, Inc.

20100081608 - Use of human chorionic gonadotropin (hcg) by oral-sublingual or injectable route as an appetite-suppressant agent.: Use of Human Chorionic Gonadotropin (hCG) by oral-sublingual or injectable route for the treatment of several food disorders, as an appetite-suppressant agent, food compulsiveness as well as all of those pathologies related to hunger and/or appetite modifications, including overweight, obesity, anorexia, bulimia, emotional hyperphagia, without excluding other pathologies associated to... Agent: Ignacio De Las Carreras

20100081610 - Matrix metalloproteinase inhibitors: The present invention relates to β-hydroxy and amino substituted carboxylic acids, which act as matrix metalloprotease inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for the synthesis of and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of... Agent: Ranbaxy Inc.

20100081611 - Stabilized maml peptides and uses thereof: Stably cross-linked a polypeptides related to human MAML are described. These cross-linked polypeptides contain at least two modified amino acids that together form an internal cross-link or tether that can help to stabilize the alpha-helical secondary structure that is thought to be important for binding of MAML peptides to the... Agent: Fish & Richardson PC

20100081615 - Continuation - site directed modification of fviii: This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.... Agent: Connolly Bove Lodge & Hutz LLP

20100081621 - Crystal structure of the catalytic domain of the viral restriction factor apobec3g: The structure, function and methods associated with proteins from the APOBEC family, which are involved in diverse biological functions, is disclosed. In one embodiment, the structure of APOBEC-3G (Apo3G) is disclosed. In another embodiment, a method of using APOBEC-3G (Apo3G) and/or Apo3G-CD2 to restrict the replication of Human Immunodeficiency Virus... Agent: Greenberg Traurig LLP (la)

20100081616 - Extracellular matrix-binding proteins from staphylococcus aureus: An isolated extracellular matrix-binding protein, designated as SdrD and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies... Agent: Stites & Harbison PLLC

20100081614 - Long-acting growth hormone and methods of producing same: A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a growth hormone and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a growth hormone are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of... Agent: Pearl Cohen Zedek Latzer, LLP

20100081613 - Methods and compositions for enhancing memory: The invention is directed to methods for enhancing memory by administering low doses of beta amyloid peptide. The invention also encompasses methods for increasing synaptic plasticity in a subject which comprises administering to the subject low doses of beta amyloid peptide.... Agent: Cadwalader, Wickersham & Taft LLP

20100081623 - Novel tellurium compounds and their use as immunomodulators: Novel tellurium-containing compounds and uses thereof as immunomodulators are disclosed.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100081619 - Peptide toxin formulation: Procedures are described which use solvents to increase the topical insecticidal activity of toxic insect peptides. These procedures comprise drying the peptides, if needed, followed by the addition of either: 1) a polar organic solvent, with or without water, to a dried peptide, or 2) the addition of polar aprotic... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz And Cohn

20100081612 - Polypeptide derivatives of parathyroid hormone (pth): The present invention is related to novel parathyroid hormone polypeptide derivatives, and to pharmaceutical composition containing the polypeptides, as well as synthetic and recombinant methods for producing the polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing the... Agent: Clark & Elbing LLP

20100081620 - Prodomain modulators of adam 10: The presently disclosed subject matter discloses isolated ADAM 10 modulating peptides and related compounds useful for studying the biological functions of ADAM 10 and for the treatment of diseases such as cancer, neurological disorders, asthma, and allergic responses, and disorders characterized at least in part by the presence of one... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20100081622 - Reduction of parathyroid hormone levels: A method of acutely reducing the plasma level of PTH of a patient having an elevated PTH comprising the administration of a pharmaceutical composition comprising a GLP-2, or a variant, an analogue, or derivative of GLP-2 having the ability to bind and activate a GLP-2 receptor such as GLP-2 1-34.... Agent: Edwards Angell Palmer & Dodge LLP

20100081617 - Therapeutic agent for spinal cord injuries: Disclosed is a therapeutic agent effective for the fundamental treatment of a spinal cord injury and a demyelinating disease. Specifically disclosed are a therapeutic agent for a spinal cord injury and a therapeutic agent for a demyelinating disease, each of which comprises an HGF protein as an active ingredient.... Agent: Knobbe Martens Olson & Bear LLP

20100081618 - Transporters comprising spaced arginine moieties: The present invention provides compositions and methods for enhancing transport of biologically active compounds across biological membranes and across and into animal epithelial or endothelial tissues. The composition includes a biologically active agent and a transport moiety. The transport moiety includes a structure selected from the group consisting of (ZYZ)nZ,... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100081624 - Selective peptides that inhibit the biological activity of calcineurin: The invention relates to the biotechnology sector involving the area of human health. More specifically, the invention is based on the surprising usefulness of peptides LxVPc1, c3 and c4 as efficient selective inhibitors of the calcineurin signalling pathway (CN)-NFAT and the phosphate activity of CN. Said compounds are useful immunosuppressors... Agent: Darby & Darby P.C.

20100081625 - Methods for preventing and treating neurodegenerative disorders: The present invention relates to a method for treating, preventing or slowing, delaying or reversing progression of one or more neurodegenerative disorders in a patient in need thereof characterized by administering a glucopyranosyl-substituted benzene derivative, a tautomer, stereoisomer, mixture or salt thereof, as defined in claim 1 to the patient... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100081705 - Methods for slowing familial als disease progression: Methods for slowing disease progression in an individual suffering from familial ALS are provided. Also provided are methods of increasing the survival time of an individual suffering from familial ALS. These methods employ antisense oligonucleotides targeted to SOD1, for use in inhibiting the expression of SOD1 in the central nervous... Agent: Jones Day For Isis Pharmaceuticals, Inc.

20100081704 - Modulator compounds of the drug resistance in epithelial tumour cells: The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphA1, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2,... Agent: Greenberg Traurig LLP (la)

20100081703 - Tri-demethylation-capable protein complex, method of its preparation and its use: The invention relates to a multiple-specificity demethylase complex comprising a Jumonji C (JMJC) domain-containing enzyme, a process of its preparation and its use.... Agent: K&l Gates LLP

20100081708 - Anticoagulant compounds: The present invention is concerned with anticoagulants (i.e. substances that stop blood from clotting). More specifically, the present invention is concerned with orally available antithrombic oligosaccharides.... Agent: Pepper Hamilton LLP

20100081711 - Cytotoxic agents: A method of killing a cell that is lacking in effective p53 protein activity, particularly as compared to wild type, is provided characterised in that it comprises delivering to the cell a single stranded DNA including a portion with at least one base, internally located with respect to any 3′... Agent: Nixon & Vanderhye, PC

20100081707 - Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea: Methods and systems for the delivery of polynucleotides to the subretinal space of the macula or fovea of an eye of a human are provided. The methods and systems are useful for treating ocular disorders.... Agent: Morrison & Foerster LLP

20100081706 - Immunomodulatory oliogonucleotides and methods of use therefor: The present invention is drawn a new class of oligodeoxynucleotides (ODNs) that inhibit ODN-activation of Toll-like receptor (TLR) 9. Particular 4-5 base extensions at the 5′ and of the previously described core inhibitory ODN sequence enhances their inhibitory activity against human cells expressing human TLR9. Methods of use also are... Agent: Fulbright & Jaworski L.L.P.

20100081709 - Isolated snare ykt6 genomic polynucleotide fragments from chomosome 7 and their uses: The invention is directed to isolated genomic polynucleotide fragments that encode human SNARE YKT6, human glucokinase, human adipocyte enhancer binding protein (AEBP1) and DNA directed 50 kD regulatory subunit (POLD2), vectors and hosts containing these fragments and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments.... Agent: Cheryl H Agris Phd

20100081710 - Modified l-nucleic acid: A modified L-nucleic acid, containing an L-nucleic acid part conjugated to a non-L-nucleic acid part is described. The conjugate has extended retention time in and demonstrates a delayed elimination from an organism.... Agent: Mdip LLC

20100081712 - Recombinant human factor ix and use thereof: The present invention aims at converting factor IX into a molecule with enhanced activity which provides an alternative for replacement therapy and gene therapy for hemophilia B. Using recombinant techniques, factor IX with replacement at positions 86, 277, and 338 exhibits better clotting activity than recombinant wild type factor IX.... Agent: Wpat, PC Intellectual Property Attorneys

20100081627 - Polymeric nucleoside prodrugs: Disclosed are polymeric compounds which are useful as prodrugs, comprising a chain of monomeric nucleosides, nucleoside analogs or abasic nucleosides, wherein at least one of the nucleosides or nucleoside analogs or a heterocyclic derivative thereof is pharmaceutically active and the nucleosides, nucleoside analogs or abasic nucleosides are linked by a... Agent: Darby & Darby P.C.

20100081626 - Weight loss compositions and uses thereof: This invention provides unique and advantageous formulations and methods for weight loss.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100081628 - Nucleoside cyclicphosphates: Cyclic phosphate of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof, represented by the following structure:... Agent: Merchant & Gould PC

20100081630 - Heparin compositions and selectin inhibition: The disclosure provides in vitro and in vivo methods for identifying Heparins and Heparinoids that modulate the activity of selectins. The disclosure also provides Heparins and Heparinoids that modulate the activity of selectins. The identification and isolation of these heparin formulations has the potential to mediate a wide variety of... Agent: Medlen & Carroll, LLP

20100081629 - Low molecular weight heparins including at least one covalent bond with biotin or a biotin derivative, method for making same and use thereof: The invention relates to biotinylated low molecular weight heparins comprising constituent polysaccharides having at their reducing ends at least one covalent bond with biotin or a biotin derivative, and also to the process for preparing them, to pharmaceutical compositions containing them and to their therapeutic use.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100081631 - Methods and compositions for treating gastrointenstial disorders: Methods are provided directed to administering a therapeutically effective amount of a prostaglandin EP4 agonist component to a mammal afflicted with or prone to affliction with a disease or condition selected from an esophageal ulcer, alcohol gastropathy, a duodenal ulcer, a gastric ulcer, non-steroidal anti-inflammatory drug-induced gastroenteropathy and intestinal ischemia.... Agent: Allergan, Inc.

20100081633 - Derivatives of 1-amino-2-cyclobutylethylboronic acid: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.... Agent: Millennium Pharmaceuticals, Inc.

20100081632 - High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders: A method of assaying protein-protein interactions associated with proteins involved in lipid pathways using a protein fragment complementation assays, said method comprising the steps of: (a) identifying protein molecules that interact with said protein associated with lipid pathways; (b) selecting a protein reporter molecule; (c) effecting fragmentation of said protein... Agent: Isaac A. Angres Suite 304b

20100081634 - Novel phosphorus-containing thyromimetics: The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and... Agent: Arnold & Porter LLP (23032)

20100081635 - Compounds for treating proliferative disorders: Disclosed are compounds of formulae (I), (III), (IV), (VII), (X), (XI), (XII), (XIII) and (XIV), wherein the variabables are as defined in the claims, and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to... Agent: Foley & Lardner LLP

20100081636 - Method for the nematocidal treatment of plants using eugenol and/or lecithin(s) and/or derivatives thereof: The invention relates to a method for the nematocidal treatment of horticulture plants, that comprises applying a composition containing a combination of lecithin(s) and/or derivative(s) thereof and of one or more terpenes or salts thereof acceptable in the food industry, or a mixture thereof.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100081637 - Eczema treatment with vitamin d and analogs thereof method, composition and cream: An eczema treatment method comprises application of a therapeutically effective composition in the form of an aqueous topical cream to an affected area of an exterior skin region of a patient, the aqueous topical cream comprising water, a water-soluble organic liquid, a surface active agent, and vitamin D3 compound or... Agent: Ater Wynne LLP

20100081638 - Compositions comprising an extract of tiarella polyphylla or compounds isolated therefrom for preventing and treating cancer diseases: The present invention relates to an anoikis-inducing agent comprising a Tiarella polyphylla extract, a tiarellic acid compound isolated therefrom or a pharmaceutically acceptable salt thereof, which is specific to cancer cells expressing a tumor-associated antigen L6 or a homolog thereof. The Tiarella polyphylla extract, the tiarellic acid compound isolated therefrom... Agent: Knobbe Martens Olson & Bear LLP

20100081639 - Pharmaceutical composition comprising fermented ginseng: A process for preparing a processed ginseng extract with enhanced pharmacological effects due to subsequent treatment is disclosed. The subsequent treatment includes an acid-treatment of ginseng and a bio-converting treatment, such as a lactic acid bacterial fermenting and an intestinal bacterial fermenting process.... Agent: Blakely Sokoloff Taylor & Zafman LLP

20100081640 - Pharmaceutical composition: A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic... Agent: Axinn, Veltrop & Harkrider LLP Attn. Michael A. Davitz

20100081643 - Novel cyclic benzimidazole derivatives useful as anti-diabetic agents: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and... Agent: Merck And Co., Inc

20100081642 - Cb-1 receptor modulator pharmaceutical formulations: The present invention relates to pharmaceutical compositions that stabilize and improve the bioavailability of 3-[(1S)- 1-(1-{(S)-(4-chlorophenyl)[3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]methyl}azetidin-3-yl)-2-fluoro-2-methylpropyl]-5-fluorobenzonitrile. In particular, the present invention relates to pharmaceutical compositions that include 3-[(1S)-1-(1-{(S)-(4-chlorophenyl)[3 -(5-oxo-4,5-dihydro- 1,3,4-oxadiazol-2-yl)phenyl]methyl}azetidin-3-yl)-2-fluoro-2-methylpropyl]-5-fluorobenzonitrile and at least one pharmaceutical acceptable excipient, such as a mono-, di- or triglyceride.... Agent: Merck And Co., Inc

20100081644 - Compounds which selectively modulate the cb2 receptor: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100081641 - Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer: The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. Formula I wherein: R1 is aminomethyl, (C1-C3 alkyl)aminomethyl, di(C1-C2 alkyl)aminomethyl, N-ethyl-N-methyl-aminomethyl, 1-aminoethyl, 1-((C1-C2 alkyl)amino)-ethyl, 3,3,3-trifluoro-propylaminomethyl, ethynyl, 2-hydroxy-ethoxy, 2-hydroxyethylaminomethyl, 2-cyanoethylaminomethyl, mopholin-4-ylmethyl, methoxymethoxymethyl, cyclopropyl, 1-azetidinylmethyl, 1-pyrrolidinylmethyl, or 1,3-dioxolan-2-yl; R2 is hydrogen or... Agent: Eli Lilly & Company

20100081645 - Tricyclic heteroaryl compounds useful as inhibitors of janus kinase: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.... Agent: Vertex Pharmaceuticals Inc.

20100081646 - Bicyclic heteroaryl inhibitors of pde4: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.... Agent: Global Patent Group - Kal

20100081647 - Short-acting benzodiazepine salts and their polymorphic forms: e

20100081648 - Methods for characterizing and treating cognitive impairment in aging and disease: This invention provides methods for identifying genes associated with cognitive impairment and for identifying compounds useful in the treatment of cognitive impairment. The methods can in particular be used to identify genes associated with, and compounds useful in treating, cognitive impairment in aging.... Agent: Ropes & Gray LLP

20100081649 - Treatment of cancers with methylol-containing compounds and at least one electrolyte: A method of inhibiting growth of a tumor cell in a mammal may include steps of administering to the mammal a first solution including a tumor-inhibiting methylol-containing compound, the first solution further including a first combination having a plurality of physiologically acceptable electrolytes or a second combination having at least... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100081650 - Antimicrobial compounds: Cyclohexane and cyclohexene derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly man.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20100081651 - R(-)-11-hydroxyaporphine derivatives and uses thereof: The invention features derivatives of R(−)-11-hydroxyaporphines and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.... Agent: Clark & Elbing LLP

20100081652 - Cinnamoyl compound and use thereof: e

20100081653 - 2-[1h-benzimidazol-2(3h)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3h)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors: 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and their salts are kinase inhibitors, useful in the treatment of cancer.... Agent: Telik, Inc. C/o Swiss Tanner, P.C.

20100081654 - Oncogenic-ras-signal dependent lethal compounds: Compounds with cancer cell specific lethality are provided. In particular, RAS-selective lethal compounds and compositions are provided. Also provided are methods of screening for such compounds and methods of treating a condition in a mammal, by administering to the mammal a therapeutically effective amount of such compounds or compositions.... Agent: Bryan Cave LLP

20100081655 - Reverse-turn mimetics and method relating thereto: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed... Agent: Seed Intellectual Property Law Group PLLC

20100081656 - Compositions and methods for modulating c-kit and pdgfr receptors: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat,... Agent: Genomics Institute Of The Novartis Research Foundation

20100081657 - Quinoxalines useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.... Agent: Vertex Pharmaceuticals Inc.

20100081658 - Heterocyclic antiviral compounds: Compounds having the formula I wherein R1, R2a, R2b, R2c, R3, Y and p are as defined herein and C2-C3 is a single or double bond are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.... Agent: Grant D. Green Roche Palo Alto LLC

20100081659 - Sigma receptor inhibitors: m

20100081660 - Novel compounds having selective inhibiting effect at gsk3: The present invention relates to new compounds, a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy, such as provide compounds having a selective inhibiting effect at GSK3.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100081661 - Heme oxygenase inhibitors, screening methods for heme oxygenase inhibitors and methods of use of heme oxygenase inhibitors for antimicrobial therapy: Inhibitors of microbial heme oxygenase and their use for treatment of microbial infections and bioremediation. The inhibitors of microbial heme oxygenase are useful against a new class of antimicrobial agents to target infections that are persistently difficult to combat with the current spectrum of antimicrobial agents. Screening methods for selecting... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100081662 - Pyrrolotriazine kinase inhibitors: h

20100081663 - Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile: Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (Cmax) and slightly delaying the peak such as... Agent: Morrison & Foerster LLP

20100081664 - Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile: Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (Cmax) and slightly delaying the peak such as... Agent: Morrison & Foerster LLP

20100081665 - Anti-malarial compounds: The present invention provides tricyclic compounds, arylamide compounds, and other compounds, and compositions comprising the same, for treating malaria, and methods of treating malaria comprising administering such compounds to an animal.... Agent: Pepper Hamilton LLP

20100081666 - Src activation for determining cancer prognosis and as a target for cancer therapy: Methods of cancer diagnosis and prognosis using biomarkers.... Agent: Womble Carlyle Sandridge & Rice, PLLC Attn: Patent Docketing

20100081667 - Chemical compounds: The present invention provides a method for the treatment of emesis in a mammal being treated with an opiod analgesic... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100081668 - Polymorphs of 5--6-chloro-1,3-dihydro-2h-indol-2-one hydrobromide and processes for preparation thereof: The present invention provides pharmaceutically applicable compounds and polymorphs belonging to the ziprasidone hydrobromide compound group with antipsychotic effect. The present invention provides hydrobromide polymorphs of 5-{-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one, ziprasidone of Formula (I) having neuroleptic activity.... Agent: Hahn & Voight PLLC

20100081669 - Pressure sensitive adhesive matrix device or system for the treatment or prevention of onychomycosis or tinea pedis: Disclosed is a pressure-sensitive adhesive matrix patch device for treatment or prevention of fungal toenails or fingernails or foot infections comprising an antifungal agent or two or more antifungals in combination and adhesively secured to a dorsal site of an infected palm or foot, rather than an area of infection... Agent: Wpat, PC Intellectual Property Attorneys

20100081671 - Cycloalkylamine substituted isoquinoline derivatives: s

20100081673 - Heteroaryl antagonists of prostaglandin d2 receptors: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100081670 - N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases: The invention provides N-pyrazinyl-phenyl-sulphonamides of formula (I) for use in the treatment of chemokine mediated diseases. Particularly inflammatory diseases, such as asthma.... Agent: Morgan Lewis & Bockius LLP

20100081672 - Ph sensitive matrix formulation: The present invention provides formulations of therapeutic agents that benefit from a prolonged time of controlled release in the stomach and upper gastrointestinal (GI) tract, and from an enhanced drug exposure to the upper GI tract. The formulations of the invention comprise a therapeutic agent and one or more pH... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20100081674 - Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes: The present invention provides compounds useful as agents for the prevention or treatment of a sex hormone-dependent disease or the like. That is, the present invention provides fused heterocyclic derivatives represented by the following general formula (I) which has a GnRH antagonistic activity, pharmaceutical compositions containing the same, medicinal uses... Agent: Sughrue Mion, PLLC

20100081675 - Fused multicyclic compounds as protein kinase inhibitors: e

20100081676 - Selective proton coupled folate transporter and folate receptor, and garftase inhibitor compounds and methods of using the same:

20100081677 - Heteroarylamide pyrimidone derivatives:

20100081678 - Indole compounds and their use as radiation sensitizing agents and chemotherapeutic agents: Indole derivatives that are useful in the treatment of cancer as a chemotherapeutic agent or radiosensitizing agent.... Agent: Stites & Harbison PLLC

20100081679 - Diaminopyrimidines as fungicides: in which R8a, R8b, R8c, R8d, R8e, R8f, R3b, R3c, R3e, X1b, X1c, X1e and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and X1, X2 and A have the meanings given in the description, and also agrochemically active salts thereof and their use for controlling unwanted... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100081680 - N-sulfonamido polycyclic pyrazolyl compounds: wherein the A-ring, B-ring, C-ring, m, n, R25, R50, and R51 are as described in the specification. The invention also provides pharmaceutical compositions comprising compounds of Formulae 1, 2, 3, and 4, as well as methods of treating cognitive disorders, such as Alzheimer's disease. The invention further provides intermediates useful... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100081682 - 39-desmethoxy derivatives of rapamycin: The present invention relates to 39-desmethoxyrapamycin derivatives and their uses thereof. The present invention provides for the use of these compounds in the treatment of cancer and/or B-cell malignancies, the induction or maintenance of immunosuppression, the treatment of transplantation rejection, graft vs. host disease, autoimmune disorders, diseases of inflammation, vascular... Agent: Wyeth LLC Patent Law Group

20100081681 - Methods and compositions for preventing or treating age-related diseases: The invention provides methods for treating or preventing an age-related disease, condition, or disorder comprising administering a therapeutically effective amount of an inhibitor of TOR to a patient in need thereof. The invention also provides pharmaceutical compositions and topical formulations for treating or preventing an age-related disease, condition, or disorder... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100081683 - Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteoraryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the a4β2 subtype... Agent: Womble Carlyle Sandridge & Rice, PLLC

20100081684 - Methods for treating inflammatory disorders: The invention described herein is based, in part, on the discovery that thieno[3,2-c]pyridine derivatives prevent inflammation in the setting of inflammatory disorders, such as asthma. Described herein are methods for treating inflammatory disorders including, for example asthma, by administering a thieno[3,2-c]pyridine derivative compound to an individual in need thereof.... Agent: David S. Resnick

20100081685 - Pharmaceutical composition: e

20100081686 - Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter: wherein R1 is a group represented by the formula: —Y1—Y2—Y3—Ra wherein Y1 is single bond or the like; Y2 is —C(═O)—NH— or the like; Y3 is optionally substituted aryl or the like; R2 is hydrogen or the like; R3 is alkyl or the like; R4 is alkyl or the like;... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100081687 - Biarylcarboxyarylamides as vanilloid-1 receptor modulators: The present invention provides compounds of formula (I): wherein A and Z are as defined in the description, along with methods for preparing such derivatives and their use for the treatment of inflammatory diseases such as neuropathic pain.... Agent: Steinfl & Bruno

20100081688 - Process for the preparation of montelukast, and intermediates therefor: The invention relates to processes for making montelukast and to intermediates for use in the process, in particular compounds of formulas 2-7: L=OAc, OTs, OTf5OMs; where X=Cl, Br, I.... Agent: Conley Rose, P.C.

20100081689 - Methods and compositions for the treatment of iron toxicity: Methods and compositions for the treatment of iron toxicity using nitroxides, particularly 4-hydroxy-2,2,6,6-tetramethyl-1-piperidine-1-oxyl (Tempol), N-acetylcysteine (NAC), and combinations thereof.... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20100081691 - Multicyclic compounds and methods of their use: This invention relates to multicyclic compounds, pharmaceutical compositions comprising them, and methods of their use in, for example, the treatment of cognitive disorders.... Agent: Lexicon Pharmaceuticals, Inc.

20100081690 - Oxazole derivatives as positive allosteric modulators of metabotropic glutamate receptors: The present invention provides new compounds of formula I, wherein P, A, W, B, Q, R1 and R2 are defined as in formula I; invention compounds are positive allosteric modulators of metabotropic receptors—subtype 5 (“mGluR5”) which are useful for the treatment or prevention of central nervous system disorders such as... Agent: Edwards Angell Palmer & Dodge LLP

20100081692 - Novel 1-benzyl-4-piperidinamines that are useful in the treatment of copd and asthma: The invention provides 1-benzyl-4-piperidinamines of the general formula (I), processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are useful in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma. The compounds are inhibitors of the CCR1 receptor.... Agent: Fish & Richardson P.C.

20100081693 - Thiadiazole compound and use thereof: wherein R is a hydrogen atom, an optionally substituted C1-C7 chain hydrocarbon group etc., Z is an oxygen atom or a sulfur atom, X is a —NR2R3 group etc., R2 and R3 each independently are a hydrogen atom, a C1-C4 alkyl group, a C3-C4 alkenyl group, a C1-C4 alkoxy group,... Agent: Panitch Schwarze Belisario & Nadel LLP

20100081695 - 2-n-{5-[ [4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione) butanedioic acid, methods of preparation and compositions with rosiglitazone maleate: e

20100081694 - Composition comprising at least one ppar agonist and a lipid component: The present invention relates to compositions comprising at least one peroxisome proliferator-activated receptor (PPAR) agonist and a lipid component and to pharmaceutical ingredients comprising said ingredients. Such compositions are particularly suitable for the prophylaxis and/or the treatment of diseases such as diabetes, obesity and hypertriglyceridemia.... Agent: Volpe And Koenig, P.C.

20100081696 - Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment: Fluoro substituted cycloalkanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.... Agent: Merck And Co., Inc

20100081697 - Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid: The invention provides a crystalline freebase form of 4′-{2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]imidazol-1-ylmethyl}-3′-fluorobiphenyl-2-carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases such as hypertension.... Agent: Theravance, Inc.

20100081698 - Crystalline modification of fipronil: The present invention relates to a crystalline modification of fipronil, to a process for the preparation of the same, to pesticidal and parasiticidal mixtures and compositions comprising said crystalline modification and to their use for combating pests and parasites.... Agent: Brinks, Hofer, Gilson & Lione

20100081699 - Yeast platform construction and screening methods: The present invention relates to a cell which is suitable for screening a candidate agent as being an inhibitor of the metabolism of tryptophan to NAD+ and/or a modulator of NAD+ levels, which cell comprises functional genes of a pathway enabling the metabolism of tryptophan to NAD+ and wherein the... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20100081700 - Hepatitis c virus inhibitors: e

20100081701 - Fap inhibitors: The present invention concerns compounds, according to general formula (I), which find utility preferably for the treatment of cancer.... Agent: Woodcock Washburn LLP

20100081702 - Pharmaceutical composition for prophylaxis or treatment of hepatitis: e

20100081713 - Compositions and methods for treating viral infections: The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infection caused by an influenza virus).... Agent: Gearhart Law LLC

20100081714 - Insecticidal mixture containing gamma-cyhalothrin: Mixtures containing gamma-cyhalothrin [(S)-α-cyano-3-phenoxybenzyl (Z)-(1R,3R)-3-(2-chloro-3,3,3-trifluoro-1-propenyl)-2,2-dimethylcyclopropanecarboxylate] and another compound having insecticidal, nematicidal, acaricidal, molluscicidal, fungicidal, plant growth regulating or herbicidal activity are provided. Compositions containing the mixture and insecticidal methods using such mixtures or compositions are also provided.... Agent: Syngenta Crop Protection, Inc., Patent And Trademark Department

20100081715 - Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof: A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof a other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically ceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the form... Agent: Paul D. Yasger Abbott Laboratories

20100081716 - Process for production of ether carboxylates: The present invention relates to a process for producing an ether carboxylate which includes the steps of (1) reacting an aliphatic monohydric alcohol with an alkylene oxide in the presence of an alkali catalyst; (2) neutralizing a reaction solution obtained in the step (1) with an acid such as hydroxycarboxylic... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100081717 - Chiral cyclic beta-amino acids and their derivatives, pharmaceutical compositions containing them and the use of such compounds: The invention relates to chiral cyclic β-amino acids of Formula (I) and their salts formed with pharmaceutically acceptable acids or bases, wherein the main meanings of the substituents are as follows: R stands for C1-4 Alk; X stands for —COOH, —CONH2, —CONH(C1-4 Alk), —CON(C1-4 Alk)2, —COO(C1-4 Alk), —COPhe-O-(C1-4 Alk) or... Agent: Young & Thompson

20100081718 - Combinations comprising alpha-2-delta ligands: The instant invention relates to a combination, particularly a synergistic combination, of an alpha-2-delta ligand and a dual serotonin-noradrenaline re-uptake inhibitor (DSNRI) or one or both of a selective serotonin re-uptake inhibitor (SSRI) and a selective noradrenaline re-uptake inhibitor (SNRI), and pharmaceutically acceptable salths thereof, pharmaceutical compositions thereof and their... Agent: Pfizer Inc. Patent Department

20100081719 - Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome: Methods for treating fatigue associated with fibromyalgia by administering high-dose milnacipran to a patient suffering from such fatigue are provided. Also provided are methods for the long-term treatment of fatigue associated with FMS by administering milnacipran to a patient suffering from such fatigue.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100081720 - Deuterium-enriched atomoxetine: The present application describes deuterium-enriched atomoxetine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20100081721 - Treatment of skin and mucosal superficial wounds using adrenergic receptor agonists: The invention generally relates to the compositions and methods related to the use of adrenergic receptor agonists solutions for the treatment of skin and mucosal superficial wounds. Some of the preferred adrenergic receptor agonists include epinephrine, phenylephrine, norepinephrine, methoxamine, and mixtures thereof. The invention also relates to devices suitable for... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100081722 - Composition and method for neuroprotection against excitotoxic injury: The present invention discloses the combined treatment of memantine (N-methyl-D-aspartate receptor antagonist) and tea polyphenol (an antioxidant and anti-inflammatory agent) is more effective (synergistic) in neuroprotection than either memantine or tea polyphenol alone in mouse excitotoxic injury. These findings provide useful information about the potential application of memantine and tea... Agent: Wpat, PC Intellectual Property Attorneys

20100081723 - Memantine for the treatment of childhood behavioral disorders: The present invention provides a method for the treatment of individuals diagnosed with a childhood behavioral disorder such as autistic spectrum disorders or combined type Attention-Deficit/Hyperactivity Disorder (ADHD) by administering an effective amount of memantine.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20100081724 - Process of obtainment of trans-resveratrol and/or emodin and nutraceuticcal compositions containing them: Processes for the separation and purification of polyphenol trans-resveratrol and/or anthraquinone emodin from Polygonum cuspidatum and/or Rumex acetosa, by means of solvent selective extraction. Products obtained by this process present high level of purity; being therefore useful in the preparation of nutraceutical (pharmaceutical and/or food) compositions with antioxidant, anti-inflammatory, antiviral,... Agent: Smith, Gambrell & Russell

20100081725 - Flavor composition or fragrance composition, product containing the flavor composition or fragrance composition, and novel ester compound: Disclosed is a 2-methyl-2-pentenyl ester represented by the general formula (1) [wherein R represents a hydrogen atom or a hydrocarbon group having 1 to 9 carbon atoms which may have a substituent]. The compound has a new-type, unprecedented aroma and/or flavor, particularly a fruity, greenish or floral aroma and/or flavor.... Agent: Mcdermott Will & Emery LLP

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141002: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 2.97567 seconds

PATENT INFO